

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

47283K

Europäisches Patentamt
European Patent Office
Office européen des brevets

BS

Publication number:

20-normal eller
20-epi ?
0078 704
A1

(B1)

EUROPEAN PATENT APPLICATION

(21) Application number: 82305821.9

(22) Date of filing: 02.11.82

VITAMIN-D ANALOGUES + USEFUL AS
VITAMIN-D LIKE THERAPEUTIC AGENTS

(51) Int. Cl.³: C 07 D 487/04, C 07 C 43/178,
C 07 C 91/15, C 07 C 103/38,
C 07 C 147/14, C 07 C 149/26,
C 07 C 172/00, C 07 D 333/72
//
(C 07 D 487/04, 237/00, 249/00),
(C 07 D 487/04, 237/00, 237/00)

(30) Priority: 02.11.81 GB 8133018
02.11.81 GB 8133019

(43) Date of publication of application: 11.05.83
Bulletin 83/19

(84) Designated Contracting States: AT BE CH DE FR GB IT
LI LU NL SE

(71) Applicant: RESEARCH INSTITUTE FOR MEDICINE AND
CHEMISTRY INC., 49 Amherst Street, Cambridge,
Massachusetts 02142 (US)


(72) Inventor: Hesse, Robert Henry, 49 Amherst Street,
Cambridge Massachusetts 02142 (US)

(74) Representative: Holmes, Michael John et al, Frank B.
Dehn & Co. European Patent Attorneys Imperial
House 15-19 Kingsway, London, WC2B 6UZ, (GB)

(54) Intermediates in the synthesis of vitamin D derivatives.

(57) Compounds of the general formula

1063



formula -Z-R³ (in which Z represents -O-, -S-, -SO-, -NR⁴- or -CR⁴R⁵- and R¹, R⁴ and R⁵, which may be the same or different, each represent a hydrogen atom or a straight or branched aliphatic group having 1-12 carbon atoms and which may optionally carry one or more substituents) and R² represents a hydrogen atom or R¹ and R² together represent an oxo group or an optionally substituted alkylidene group, except that R¹ and R² together with the group -CH(CH₃)CH- to which they are attached do not represent a group having the branched 17β-hydrocarbyl side chain skeleton of vitamin D₂ or vitamin D₃ of use in the preparation of novel vitamin D analogues.

47283K

wherein R represents a hydrogen atom or a hydroxyl protecting group, Y represents a hydrogen atom or an optionally protected hydroxyl group, X represents the residue of a dienophile and either R¹ represents a halogen atom a hydrocarbylsulphonyloxy group or a group of the

ACTORUM AG

EX 27 + 25

GS2138
GS2139
MIXTURE

GS1810

EP 0 078 704 A1

0078704

"Chemical Compounds".


This invention relates to novel intermediates in the production of vitamin D analogues and a method for their production.

In the past modified vitamin D derivatives have been prepared through modification of sterol precursors which are then converted into vitamin D derivatives through a standard series of steps, normally preliminary conversion of $\Delta^{5,7}$ dienes followed by irradiation of the dienes to give D vitamins. These procedures have serious flaws. First, all of the available methods for the synthesis of $\Delta^{5,7}$ dienes tend to give mixtures of products or require a number of steps and proceed in relatively low yield. The second difficulty is that the only known transformation of the $\Delta^{5,7}$ dienes into the vitamins involves irradiation followed by thermal equilibration. Irradiation intrinsically gives rise to a mixture of byproducts. This limits the yield of the desired vitamin and furthermore complicates its recovery in pure form.

Previous attempts to modify the 17-side chain of vitamin D compounds have been unsuccessful due to instability problems. We have now found that vitamin D₂ and related compounds can be converted to a protected form capable of withstanding the reaction conditions necessary for oxidative cleavage of the 22,23-double bond to form a 22-aldehyde which can then be converted to other derivatives as described hereinafter. In particular, we have found that vitamin D₂ compounds in either the cis or trans configuration can be stabilised by formation of a Diels Alder dienophile adduct which can subsequently be reconverted to the trans form of the vitamin after the side-chain modification. The trans vitamin analogues can then be efficiently converted into the active cis form by known reactions.

0078704

According to one feature of the present invention we provide compounds of the general formula I,



wherein R represents a hydrogen atom or a hydroxyl
 5 protecting group, Y represents a hydrogen atom or an optionally protected hydroxyl group, X represents the residue of a dienophile and either R¹ represents a halogen atom a hydrocarbylalkylphenoxy group or a group of the formula -Z-R³ (in which Z represents
 10 -O-, -S-, -SO-, -NR⁴ or -CR⁵- and R³, R⁴ and R⁵ which may be the same or different, each represents a hydrogen atom or a straight or branched aliphatic group having 1-12 carbon atoms and which may optionally
 15 carry one or more substituents) and R² represents a hydrogen atom or R¹ and R² together represent an oxo group or an optionally substituted alkylidene group, except that R¹ and R² together with the group
 20 -CH(CH₃)CH- to which they are attached do not represent a group having the branched 17β-hydrocarbyl side chain skeleton of vitamin D₂ or vitamin D₃.


The above compounds are useful intermediates in the preparation of vitamin D analogues i.e. compounds of general formulae IV and IVa

1065

47283K

- 1 -

0078704



IVa (cis)

IV (trans)

wherein R, Y, R¹ and R² are as hereinbefore defined. The above compounds of general formulae IV and IVa are also novel and constitute a still further feature
 5 of this invention.

The use of the compounds of general formula I in the preparation of the novel compounds of formulae IV and IVa is illustrated in the reaction scheme of the accompanying drawings, R, Y, X, R¹ and R²
 10 being as defined above. The compounds of formula I-IV may also carry further groupings.

It should be noted that the Diels Alder adduct formed from either the 5,6-cis- or the 5,6-trans-
 15 vitamin starting material exists as a mixture of two possible isomers at the 6-position. However, since the eventual removal of the Diels Alder residue always generates a compound of the 5,6- trans configuration, there is no need to distinguish between such 6-isomers
 20 or to effect their separation.

We have found that using the above procedure a wide range of groups R¹ may be introduced into the vitamin D structure. Thus, as indicated above R¹ may be a group of the formula Z-R³, where Z is
 25 -O-, -S-, -SO-, -NR⁴ or -CR⁵- and R³, R⁴ and R⁵ which may be the same or different, are each a hydrogen atom or a straight or branched aliphatic group having
 1066

47283K

1-12 carbon atoms which may carry one or more substituents such as, for example halogen atoms (e.g. fluorine), or optionally protected hydroxyl groups.

In general it is preferred that the group R³ in the final products should be of the formula



(in order to provide a 178- side chain of approximately the shape present in natural vitamin D compounds) with the possibility of substitution as described above. The heteroatoms Z, where present, do not greatly change the overall shape of the side chain.

In particular, the invention enables compounds of formula IV and IVa to be prepared in which R¹ is of formula



wherein Z' represents -O-, -S-, -NH- or -SO- and R⁶ represents a hydrogen atom or a hydroxyl protecting group, the 1α-position optionally carrying a hydroxyl or protected hydroxyl group, these being analogues of the active metabolite 25-hydroxy vitamin D³.

Protected hydroxyl groups may, for example, be acyl groups e.g. alkanoyl groups (preferably having 1-6 carbon atoms), aralkanoyl groups (preferably having 7-15 carbon atoms), aryl groups (preferably having 6-12 carbon atoms), cyclic ether groups or tri-hydrocarbylsilyl groups. Examples of such groups include acetyl, propionyl, benzoyl and tetrahydropyranyl groups and trihydrocarbylsilyl groups having up to three C₁₋₆ alkyl, C₆₋₁₂ aryl and/or C₇₋₁₅ aralkyl groups.

1067

47283K

The new synthetic analogues of the invention have modified vitamin D properties of interest in medicine.

The compounds of formulae IV and IVa in which R¹ has the above meanings may be prepared, inter alia, by nucleophilic substitution reactions on compounds of formula IV and IVa in which R¹ represents a halogen atom, such as a chlorine, bromine or iodine atom, or a leaving group, for example a hydrocarbylsulphonyloxy group O-SO₂R⁷ in which R⁷ represents, for example, an alkyl group (preferably having 1-6 carbon atoms), an aryl group (preferably having 6-12 carbon atoms) or an aralkyl group (preferably having 7-15 carbon atoms). The tosyloxy group is preferred. Alternatively, the above compounds may be prepared from corresponding compounds of formula I and the dienophile group X removed subsequently. Since, however, the nucleophilic substitution reactions are mostly carried out in the presence of a base and since the protected compounds of formula I are less stable to base than the parent trienes of formula IV and IVa, the latter are commonly preferred substrates.

In the formation of 22-thia compounds (in which Z is -S-), the nucleophilic reagent is conveniently the thiol of formula R³XH reacted in an inert solvent such as tetrahydrofuran in the presence of a non-nucleophilic base, for example an inorganic base such as sodium hydride or an organic base such as pyridine.

The corresponding sulfoxides (Z = -SO-) may be prepared by oxidation of the thia-compound (Z = -S-), for example using a peracid or salt as oxidising agent, e.g. a periodate. Mixtures of the (R) and (S) sulfoxides are normally formed and the invention extends to these separately and in admixture.

The 22-oxa compounds of formula IV or IVa may be prepared by reaction of an alcohol of formula I, IV or IVa in which R¹ is OH, with an alkylating agent

1068

47283K

or alternatively by reaction of a reactive derivative thereof, with an alcoholate; these reactions are followed by deprotection.

I is used. The reactive derivative may, for example, be a halide such as an iodide, or a hydrocarbylsulphonyloxy derivative, such as a tosyloxy derivative, the alcoholate being, for example, an alkali metal or thallium alcoholate of the alcohol R³OH. It is preferred, however, to react the compound of formula (I) with an alkali metal, such as sodium, potassium, or lithium, in the presence of a solvent, such as dimethyl sulfoxide, to form an alkali metal salt of the compound of formula (I).

10 Va in which R¹ is OH with an epoxide. This generates a side chain carrying a hydroxyl group derived from the epoxide oxygen. Where it is desired to make 25-hydroxy-22-oxa vitamin D₃ derivatives, a suitable reagent is isobutylene epoxide.

15. The reaction is advantageously effected in an inert solvent, e.g. a hydrocarbon solvent such as benzene, in the presence of a non-nucleophilic base, conveniently an alkali metal t-alkoxide in the presence of a phase transfer agent such as a crown ether. Under such basic conditions, we have found it especially preferred to effect the reaction on a starting compound of formula IV or IVa, since the trienes are, as indicated above, more stable to these conditions than the dienophilic protected compounds of formula V or Vb.

The 22-aza compounds of formula I, IV or IVA may be prepared by reaction of a reactive derivative of an alcohol of formula I, IV or IVA in which R¹ is OH, for example a halide such as an iodide, or a hydrocarbylsulphonyloxy derivative such as a tosyloxy derivative, with an amine of formula R³R⁴NH. Due to the basicity of the reagent, a substrate of formula IV or IVA is preferred. Where the amine is liquid it is preferably reacted without added solvent.

The 22-aza derivatives may often conveniently be isolated as N-acylates, such as N-acetates, which may be formed by reaction with an appropriate acid anhydride.

1069

47283K

47203K

The 22-hydrocarbonylsulphonyloxy derivatives of formulae I, IV and IVa used in the above reactions may be prepared by reacting the corresponding alcohol with the appropriate hydrocarbonylsulphonyl halide, e.g. tosyl chloride in the presence of a base such as pyridine. Best results have been obtained by effecting this reaction on a compound of formula I in which X is SO₂, and removing the SO₂ residue by thermolysis, as described hereinafter.

The compounds of formula I, IV or IVA in which Z in R¹ is CR⁴R⁵ may be prepared by reacting compounds of formula I, IV or IVA carrying a hydrocarbylsulphonyloxy group R¹, e.g. a tosyl group, with carbon nucleophiles. Suitable carbon nucleophiles are Grignard reagents reacted in the presence of a copper catalyst, e.g. a cuprous salt. Thus, for example, 25-hydroxy vitamin D₃ and the 1 α -hydroxy derivative thereof may be prepared by reacting an appropriate hydrocarbylsulphonyloxy derivative of formula I, IV or IVA with a Grignard reagent of the formula




(where R^6 has the above meaning) Δ^n tetrahydrofuran in the presence of cuprous iodide.

For the production of an alcohol of formula I in which R^1 is OH, for use in the preparation of the above novel vitamin D derivatives, the formyl group in the corresponding aldehyde of formula I (wherein R^1 and R^2 together represent oxo) must be reduced.

We have found that this can be effected readily, often in essentially quantitative yield, by reaction with a metal hydride-reducing agent such as an alkali metal borohydride, e.g. sodium borohydride. It is noteworthy that this reduction retains the original configuration at the 20-carbon atom. Such alcohols are also new compounds.

0078704

Compounds of formula I, IV or IVa may also be prepared in which R¹ is a divalent alkylidene group, which may carry substituents as described above for R³. Thus, for example, the aldehyde of formula I (wherein R¹ and R² together represent oxo) may be reacted with an ylide, for example a Wittig reagent which may be represented by the general formula



wherein the groups R⁸, which may be the same or different, are alkyl (preferably C₁₋₆), aralkyl (preferably C₇₋₁₅) or aryl (preferably C₆₋₁₂) groups and R^{1A} is an alkylidene group (preferably having 1 to 8 carbon atoms) and may carry substituents as described for R³ above.

The Wittig reagent will normally be formed in situ by reaction of a quaternary salt thereof with a strong base in an inert solvent. Suitable bases include hydrocarbyl lithium compounds such as phenyl lithium and *n*-butyl lithium. Suitable solvents include ether solvents such as tetrahydropyran and diethyl ether. The aldehyde of formula I is preferably added immediately after the Wittig reagent has been formed.

The phosphonium salt precursor of the appropriate Wittig reagent for formation of the correct 178-side chain of 25-hydroxy vitamin D₃ may, for example be prepared by reaction of isobutylene epoxide with methylenetriphenylphosphorane, the initially formed product in which R⁵ is H may if desired be protected, for example by formation of a tetrahydropyranyl or trihydrocarbylsilyl derivative. The phosphorane is preferably prepared by reaction of methyltriphenylphosphonium bromide in a cyclic ether solvent such as tetrahydrofuran in the presence of a strong base such as phenyl or *n*-butyl lithium, the isobutylene epoxide then being reacted in situ with a second equivalent of base. We have found the phosphonium bromide initially produced to be difficult to isolate

0078704

and purify but that conversion to a tetraphenylborate salt enabled a relatively pure product to be obtained.

If it is desired to form a saturated side-chain, selective reduction of the newly formed 22,23-double bond is required. This was unexpectedly found to be possible using hydrogenation over 5% palladium on charcoal. It is noteworthy that this reduction restores the desired, "natural" configuration at the 22- and 23- carbon atoms. This route thus provides a further method of preparing compounds of formula I, IV or IVa in which R¹ is -CH₂CH₂R³, as defined above.

It will be seen that the compounds of formula I in the above reaction scheme are key intermediates in the production of the new vitamin D analogues according to the invention. By way of illustration their preparation is now described in detail starting from vitamin D₂ or its 5,6-trans isomer.

The compound of formula III may be prepared by reaction of a vitamin D₂ compound of formula IIa or IIb with a dienophile whereby the desired divalent grouping X is introduced.

The dienophile may, for example, be SO₂ or a diacylazo compound. Preferred azo dienophiles are cyclic azo compounds such as phthazine diones or triazoline diones; in general these may be represented by the formula V,

1072



where W is a divalent aromatic carbocyclic group such as a 1,2-phenylene group or a group N-R^9 where R^9 is an aryl group such as a phenyl group. The divalent aromatic group or the aryl group R^9 may carry substituents, for example C1-6 alkyl or alkoxy groups, halogen atoms or nitro groups. Derivatives of formula III in which X is of formula V are also new compounds.

Where the dienophile is SO_2 , this may simply be reacted with the vitamin D_2 compound in a suitable solvent, for example aqueous media capable of dissolving the vitamin. A well stirred mixture of water and a hydrocarbon solvent such as benzene is particularly useful. Basic conditions are preferably used, e.g. using an inorganic base such as an alkali metal bicarbonate.

Where the dienophile is a cyclic azo compound of formula V in which W is a group N-R^9 , this may be added to the starting vitamin D_2 compound in solution

in a suitable solvent such as ethyl acetate. Where W is a divalent-1,2-arylene grouping as in phthalazine 1,2-dione, however, this is preferably formed in situ by oxidation of the corresponding cyclic hydrazide, e.g. phthalhydrazide. Thus the vitamin D_2 compound

may be reacted in solution in an inert solvent such as a halogenated hydrocarbon with the cyclic hydrazide in the presence of an oxidising agent such as lead tetraacetate/acetic acid.

After formation of the adduct of formula III, the 22,23-double bond may be cleaved to form the 22-formyl derivative of formula I by known oxidative techniques such as permanganate/periodate, osmate/periodate or, most preferably ozonolysis. We have found that this reaction proceeds selectively in high yield with little cleavage of the 7,8-double bond and, in particular, with no disturbance of the stereochemistry at the 20-position.

Ozonolysis may be effected by passing ozone, preferably diluted with a further gas such as oxygen,

1073

47283K

through a solution of the compound of formula III in a solvent therefor to form an ozonide which is then reductively cleaved by a suitable reducing agent.

A suitable solvent is, for example, a halogenated hydrocarbon such as dichloromethane, a ketone, e.g. methyl ethyl ketone or acetone or an alcohol such as methanol or ethanol. A mixture of dichloromethane and methanol gave especially good yields. The reducing agent may be present during the reaction or added

after ozonide formation is completed. Thus, for example tetracyanoethylene may be present in solution in acetone during ozonolysis. While reducing agents such as dimethyl sulphide may be used to reduce the ozonide after its formation, preferred reagents are

trivalent phosphorus compounds such as triphenylphosphine. Where an alcohol solvent is used, the aldehyde product of formula I may form an acetal derivative with the alcohol. This may, however, readily be cleaved hydrolytically, for example using an aqueous base e.g. sodium bicarbonate. The reaction is preferably carried out at low temperatures, for example -78°C .

After modification of the 17-side chain, the dienophile residue X may be removed to yield, as indicated above, a 5,6-trans vitamin of general formula IV. The removal of the residue X will be effected in different ways, depending on its nature.

Where X is SO_2 , it is conveniently removed by thermolysis under basic conditions, e.g. in the presence of a hydroxylic solvent such as an alcohol, e.g. ethanol, containing a base such as an alkali metal carbonate, e.g. sodium carbonate.

Where X is a group of formula V, removal can readily be effected by removal of the $-\text{CO}-\text{N}-\text{CO}-$ moiety, for example by basic hydrolysis or treatment with hydrazine, followed by mild oxidation of the unsubstituted vitamin hydrazide so formed to the corresponding

azo-compound which spontaneously decomposes to yield the required 5,6-trans vitamin. Azo-hydrolysis

1074

47283K

can be effected using strong alkali such as sodium or potassium hydroxide, for example in solution in an alcohol such as methanol, or by treatment with an amine such as triethylamine. The preferred method, however, is treatment with hydrazine which produces the desired hydrazide in high yield; this reaction has not previously been described for decomposition of such Diels-Alder adducts. Oxidation may be effected using reagents capable of oxidising hydrazo compounds to azo compounds, for example ceric, cupric, ferric, ferricyanic or periodate salts or air. A preferred mild reagent, however, is a diaryl telluroxide such as dianisyl telluroxide, preferably used with a re-oxidant such as 1,2-dibromotetrachloroethane and a base such as K_2CO_3 as described in our British patent specification No. 2059758A.

Where a 1a-hydroxy vitamin D compound is required, the modified 5,6-trans-vitamin compound of formula IV, which carries the desired 17-side chain, optionally protected, may be subjected to 1a-hydroxylation, using the procedure of our South African patent No. 79/5958. Thus, the 5,6-trans vitamin compound may be reacted with a selenite ester, preferably formed *in situ* by reaction of selenium dioxide and an alcohol such as methanol. The quantity of selenium compound may be reduced if a re-oxidant is employed, for example a periodate salt or N-methyl morpholine 1-oxide.

Alternatively, a reactive derivative of a 22-hydroxy derivative of formula I-95-IV above may be 1a-hydroxylated by the above procedure and the desired side-chain built up subsequently.

The 5,6-trans vitamin D compound of formula IV, after modifications such as those described above, may readily be isomerised in high yield to a required active *cis*-vitamin compound by known techniques, for example by irradiation in the presence of iodine or diphenyl selenide or, preferably, a triplet photosensitizer having a triplet energy of the order of 45 ± 1075 .

47283K

5. Kcal per mole, such as anthracene, acridine or phenazine. To avoid isomerisation to undesired tachysterol derivatives, acid conditions should be avoided and the photoisomerisation is preferably effected in the presence of a base such as triethylamine.

Where protected hydroxyl groups are present in the vitamin product, these may be removed by conventional methods. In general, the vitamin structure is somewhat sensitive to acids, but is resistant to basic conditions and the latter are advantageously used. Acyloxy groups can thus be removed using alkali metal hydroxide in an alcohol solvent such as methanol. Silyl groups may be removed by treatment with quaternary ammonium fluorides such as tetra-n-butylammonium fluoride. Since most of the reactions described above can be applied to compounds having unprotected hydroxyl groups, protecting groups may be removed, if desired, at various stages. Although the vitamins are resistant to bases (and sensitive to acids), the dienophile adducts tend to be sensitive to bases and relatively resistant to acids. Consequently, acid conditions may be used to deprotect hydroxyl groups at stages where the dienophile residue X is present.

In general, most of the stages described above proceed in excellent yield. When conditions are optimised, yields of the order of 80% or more at each stage have been achieved. This renders the overall yield of modified vitamin, starting from vitamin D₂, markedly better than those achieved using many previously suggested routes.

1076

47233K

The following examples are given by way of illustration only:-

Microanalyses and mass spectra were obtained by the staff at the Institut de Chimie des Substances Naturelles du CNRS, Gif-sur-Yvette, France. Melting points were determined using either a Kofler block, Mel-Temp or Fisher-Johns apparatus and are uncorrected. Optical rotations were measured at room temperature using a Rudolph Photo-

electric Polarimeter, Model 70, and are reported for chloroform solutions unless otherwise stated. UV spectra were recorded using a Carey

10 11 spectrophotometer and are reported for ethanol solutions. The molar extinction coefficient (ϵ) for these absorbances are given in parenthesis. IR spectra were recorded using a Perkin-Elmer 137 "Infracord" spectrophotometer and are reported for KBr discs unless

otherwise stated. Absorbance characteristics are denoted by s = strong, m = medium, w = weak, sh = shoulder, br = broad. ^1H NMR spectra were determined at 60MHz on a Varian T-60 spectrometer. NMR characteristics

are denoted as s = singlet, d = doublet, tr = triplet, q = quartet, m = multiplet, W = peak width at half height and are reported for CDCl_3 solutions, unless otherwise indicated, with tetramethylsilane as internal standard, as values of δ (ppm downfield of TMS). Thin layer chromatography (tlc) was carried out on 250 μ silica

gel GHLF "Uniplates" (Analtech, USA); and preparative layer chromatography (plc) on 1mm silica gel GF-254 "Uniplates" (Analtech, USA). "Chromatography" refers to medium pressure liquid chromatography

25 carried out using E. Merck silica gel 60H. High performance liquid chromatography (HPLC) was carried out using Waters Associates silica gel "Porasil A" packed in two 2 ft x 3/8 inch stainless steel columns,

1077

47283K

and a Waters Associates chromatograph, equipped with a 6000 psi pump and a differential refractometer detector. Ozone was generated from a Towers Ozone Apparatus GE-150. Selective ozonolysis requires vigorous mixing of the dissolved substrate and the oxygen-ozone gaseous mixture. A "Vibromixer" (Chemapag, Switzerland) equipped with a stainless steel gas inlet/stirrer was particularly useful for this purpose. This equipment was also used for the formation of the phthalazine-1,4-dione Diels-Alder adducts of vitamin D.

A 200W Hanovia medium pressure mercury vapour lamp (654A36) was used as irradiation source for 5,6-double bond photoisomerisation reactions.

Reactions on calciferol substrates were routinely performed under an inert, argon atmosphere. Calciferols were stored at -20°C, under argon, in the dark, as either crystalline solids or (where possible) ether solutions. Solvents used were reagent grade unless otherwise stated.

Aqueous work-up refers to partition between an organic solvent and water, followed by sequential washing with a 5% aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution. The organic solution was dried using either anhydrous MgSO_4 or anhydrous Na_2SO_4 , and the solvent removed on a rotary evaporator. Acid work-up refers to partition between an organic solvent and water, followed by sequential washing with a 4% aqueous HCl solution; 5% aqueous sodium bicarbonate solution, etc. as for aqueous work-up.

1078

47282K

Example 1

(a) 6(R),19-[4'-phenyl-1',2',4'-triazolidine-3',5'-dione-1',2'-yl]-9,10-seco-3 β -hydroxy-ergosta-5(10), 7(E), 22(E)-triene

To ergocalciferol (5g) in ethylacetate (150 ml) at 0°C under an argon atmosphere, 4-phenyl-1,2,4-triazoline-3,5-dione (2.4g, 1.1 eq) in ethyl acetate (150 ml) was added over 45 min. After a further 1 hr, some of the title adduct had precipitated. The mixture was filtered and the filtrate passed down a neutral alumina column.

Elution with hexane/ethylacetate gave the remainder of the product.

10 Crystallisation from alcohol gave 6.2g (86%). mp 99°C; $[\alpha]_D^{20} = +208^\circ$ (c = 0.76); $^1\text{Hnmr}$ δ 7.48 (s, 5H, aryl), 5.22 (m, W = 10Hz, C-22H, 23H), 4.98 and 4.73 (an AB system, J = 10Hz, C-6H, 7H), 4.2 and 3.85 (an AB system, J = 15Hz, C-19H₂), 4.1 (m, C-3H), 0.53 (s, C-18H₃). IR ν_{max} (CHCl₃) 3700 (br), 2950 (s), 1775 (m), 1710 (s), 1425 (s) cm⁻¹; mass spec. molecular ion, m/e = 571; (analysis found: % C, 75.62; H, 8.64; N, 7.35).

15 Similarly prepared from ergocalciferol acetate in 85% yield was the corresponding acetate 6(R),19-[4'-phenyl-1',2',4'-triazolidine-3',5'-dione-1',2'-yl]-9,10-seco-3 β -acetoxy-ergosta-5(10), 7(E), 22(E)-triene.

20 Crystallised from ethanol. m.p. 85°C; $[\alpha]_D^{20} = +183^\circ$ (c = 0.82); $^1\text{Hnmr}$ δ 7.48 (s, 5H, aryl), 5.22 (m, W = 12Hz, C-3H, 22H, 23H), 4.98 and 4.73 (an AB system, J = 10Hz, C-6H, 7H), 4.2 and 3.85 (an AB system J = 16Hz, C-19H₂), 2.0 (s, OAc), 0.53 (s, C-18H₃); IR ν_{max} (CHCl₃) 2950 (s), 2900 (sh), 1725 (s), 1420 (m) cm⁻¹; mass spec. molecular ion m/e = 613; (analysis found: % C, 74.18; H, 8.11; N, 6.65; C₃₈H₅₁O₄N₃; requires: % C, 74.35; H, 8.38; N, 6.85).

1079

47283K

(b) Ozonolysis

The adduct from (a) above (250mg) in acetone (10 ml) containing tetra-cyanoethylene (55mg, 1 eq) at -78°C was treated with ozone for 3 min (approx. 1.5 eq). The system was purged with argon whilst warming to room temperature. The product mixture was separated by plc to give.

130mg of starting material (nmr) and the corresponding 20(S)-formyl derivative (90mg, 84%) as a white foam. $^1\text{Hnmr}$ δ 9.55 (d, J = 3.75Hz, C-22H), 7.45 (s, 5H, aryl), 5.15 (m, W = 12Hz, C-3H), 4.92 and 4.82 (an AB system, J = 10Hz, C-6H, 7H), 4.18 and 4.70 (an AB system J = 10 Hz, C-19H₂), 2.0 (s, OAc), 1.12 (d, J = 7H, C-21H₃), 0.57 (s, C-18H₃).

Example 2

(a) Reaction of ergocalciferol acetate with phthalazine-1,4-dione

Phthalhydrazide (10g, 2.5 eq) was suspended in a solution of ergocalciferol acetate (10g) in dry CH₂Cl₂ (200 ml). The efficiently mixed mixture was cooled to 0°C, and a solution of lead tetra-acetate (20g) in dry CH₂Cl₂ (100 ml) and acetic acid (1 ml) was added dropwise. The reaction was monitored by tlc. Upon completion, the residual

phthalhydrazide was filtered off. Aqueous work-up followed by careful

20 crystallisation from ethylacetate gave 7.4g (54%) of 6(R),19-[N,N'-

phthalhydrazido]-9,10-seco-3 β -acetoxy-ergosta-5(10), 7(E), 22(E)-triene.

m.p. 202-203°C; $[\alpha]_D^{20} = +343^\circ$ (c = 1.02); UV λ_{max} 238nm

1080

47233K

0078704

(38250) and 312nm (11300); $^1\text{Hnmr}$ δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 5.08 (m, W = 10Hz, C-3H, 22H, 33H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 2.0 (s, OAc), 0.13 (s, C-18H₃); IR ν_{max} 2950 (s), 2900 (sh), 1750 (s), 1660 (s), 1610 (m), 1380 (m), 1355 (m), 1250 (s) cm^{-1} ; mass spec. molecular ion m/e = 598; (analysis found: % C, 75.92; H, 8.30; N, 4.61; $\text{C}_{38}\text{H}_{50}\text{N}_4\text{O}_2$ requires: % C, 76.22, H, 8.42; N, 4.68). The mother liquors were chromatographed on silica gel to give 3.6g (26%) of essentially pure 6(S),19-[N,N'-phthalhydrazido]-9,10-seco-3 β -acetoxy-ergosta-

10 5(10), 7(E), 22(E)-triene. Solid from CH_2Cl_2 /hexane. m.p. 114-

116°C; $[\alpha]_D^{25} = -306^\circ$ (c = 0.64); $^1\text{Hnmr}$ δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 6.0 (d, J = 10Hz, C-7H), 5.2 (m, W = 10Hz, C-3H, 22H, 23H), 4.83 (d, J = 10Hz, C-6H), 4.78 and 4.23 (an AB system, J = 18Hz, C-19H₂), 2.17 (s, OAc), 0.65 (s, C-18H₃); IR ν_{max} 2950 (s), 15 2900 (sh), 1650 (s), 1610 (m), 1380 (m), 1355 (m), 1250 (s) cm^{-1} ; mass spec. molecular ion m/e = 598.

(b) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3 β -hydroxy-ergosta-5(10), 7(E), 22(E)-triene

To the acetate from (a) above (5g) in benzene (100 ml) were added NaOH/-20 CH_3OH (1.25 M solution, 12 ml). After 20 min, the mixture was diluted with water and CH_2Cl_2 . Acid work-up gave an essentially quantitative yield (4.5g) of the title 3 β -hydroxy compound, crystalline from CH_2Cl_2 /ether. m.p. 169-171°C; $[\alpha]_D^{25} = +392^\circ$ (c = 0.773); $^1\text{Hnmr}$ δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, 25 C-7H), 5.12 (m, W = 9Hz, C-22H, 23H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 4.1 (m, C-3H), 0.18 (s, C-18H₃). IR ν_{max} 3550 (br), 2950 (s), 2900 (sh), 1650 (s), 1081

47283K

0078704

1610 (m), 1375 (m), 1350 (m) cm^{-1} ; mass spec. molecular ion m/e = 556; (analysis found: % C, 77.76; H, 8.78, N, 5.17; $\text{C}_{36}\text{H}_{48}\text{O}_3\text{N}_2$ requires: % C, 77.66; H, 8.69; N, 5.03.

(c) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3 α -tetrahydropyranyloxy-ergosta-5(10), 7(E), 22(E)-triene

The alcohol from (b) above (4.5g) in benzene (100ml) was stirred overnight with dihydropyran (10 ml) and p-toluene sulphonic acid (10mg). Aqueous work-up gave the title THP ether (204c) (5g, 96%). Crystalline from CH_2Cl_2 /ether. m.p. 151-154°C; $[\alpha]_D^{25} = +332^\circ$ (c = 1.25); $^1\text{Hnmr}$ δ 8.3 (m, W = 12Hz, 10 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 5.07 (m, W = 9Hz, C-22H, 23H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 4.7 (m, THP, C-2'H), 4.02 (m, C-3H), 3.5 (m, W = 20Hz, THP, C-6'H₂), 0.17 (s, C-18H₃); IR ν_{max} 2950 (s), 2900 (sh), 1650 (s), 1610 (m), 1370 (s), 1350 (s), 1030 (s) cm^{-1} ; mass spec. molecular ion m/e = 15 640.

(d) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3 β -[t-butylidimethylsilyloxy]-ergosta-5(10), 7(E), 22(E)-triene

The alcohol from (b) above (4.5g) in CH_2Cl_2 (20ml) was treated with t-butyl-dimethylsilylchloride (1.9g) and imidazole (2.7g) at room temperature for 1.5hr. Addition of water followed by acid work-up and crystallisation from CH_2Cl_2 /hexane gave 5.1g (94%) of the silyl ether. m.p. 203-205°C; $[\alpha]_D^{25} = +313^\circ$ (c = 1.5); $^1\text{Hnmr}$ δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 5.08 (m, W = 9Hz, C-22H, 23H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 25 4.03 (m, C-3H), 0.88 (s, t-butyl), 0.17 (s, C-18H₃), 0.07 (s, Si-CH₃).

1082

47233K

0078704

0.05 (s, Si-CH₃); IR ν_{max} 2950 (s), 2900 (sh), 1650 (s), 1610 (m), 1370 (s), 1350 (s), 1090 (s) cm⁻¹; mass spec. molecular ion m/e = 670; (analysis found: % C, 74.98; H, 9.26; N, 4.13; C₄₂H₆₂O₄N₂Si requires: % C, 75.18; H, 9.31; N, 4.18).

- 5 (e) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3β-methoxyethoxymethoxy-ergosta-5(10), 7(E), 22(E)-triene

The alcohol from (b) above (4.5g) in CH₂Cl₂ (100 ml) was stirred overnight at room temperature with methoxyethoxymethylchloride (8ml) in the presence of diisopropylethylamine (20 ml). Acid work-up followed by chromatography and crystallisation from CH₂Cl₂/hexane gave 4.3g (83%) of the MEM ether. m.p. 123-125°C; [α]_D = +325° (c = 1.295); ¹Hnmr δ 8.3

10 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 5.15 (m, W = 9Hz, C-22H, 23H), 4.82 (s, -OCH₂O-), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 4.0 (m, C-3H), 3.67 (m, W = 6Hz, -OCH₂CH₂O-), 3.43 (s, OCH₃), 0.18 (s, C-18H₃); IR ν_{max} 2950 (s), 2900 (sh), 1650 (s), 1610 (m), 1470 (m), 1450 (m), 1370 (s), 1340 (s), 1100 (s), cm⁻¹; mass spec. molecular ion m/e = 644; (analysis found: % C, 74.72; H, 8.57; N, 4.13; C₄₀H₅₆O₄N₂ requires: % C, 74.50; H, 8.75; N, 4.34).

- 20 (f) General procedure for the ozonolysis of the ergostane side chain

The adduct from (a), (c), (d) or (e) above (4-5g) in CH₂Cl₂ (130ml) and methanol (60ml) was cooled to -78°C. The efficiently mixed solution was treated with an ozone-oxygen mixture (approx. 1mmol O₃/min) for 8-12 min (tlc control) and then thoroughly purged with dry argon for approx. 5 min. Triphenyl phosphine (2.5-3g) was added and the mixture, after approx.

1063

47283K

0078704

30 min at -78°C (tlc monitoring of the breakdown of the methoxyhydroperoxide intermediates) was shaken with 5% aqueous NaHCO₃ (to prevent dimethyl acetal formation) and allowed to warm to room temperature. The layers were separated and the organic solution dried. Chromatography through 5 silica gel (40-50g) gave the aldehyde (75-86%) free from any of the C-20(R) epimer (nmr). The following compounds were prepared in this manner.

- 1) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3β-acetoxy-20(S)-formyl-pregna-5(10), 7(E)-diene

10 Crystalline from CH₂Cl₂/ether. m.p. 192-193°C; [α]_D = +302° (c = 1.235); ¹Hnmr δ 9.55 (d, J = 3Hz, C-22H), 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 5.17 (m, C-3H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 2.07 (s, OAc), 1.07 (d, J = 7Hz, C-21H₃), 0.22 (s, C-18H₃); IR ν_{max} 15 (CHCl₃) 2950 (m), 2900 (sh), 1740 (s), 1645 (s), 1610 (m), 1370 (m), 1350 (m), cm⁻¹; mass spec. molecular ion m/e = 530; (analysis found: % C, 72.13; H, 7.12; N, 5.20; C₃₂H₃₈O₅N₂ requires: % C, 72.43; H, 7.22; N, 5.28).

- 2) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3β-tetrahydropyranyloxy-20(20(S)-formyl-pregna-5(10), 7(E)-diene

Crystalline from CH₂Cl₂/ether. m.p. 154-156°C; [α]_D = +356° (c = 0.84); ¹Hnmr δ 9.42 (d, J = 3Hz, C-22H), 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 4.69 (m, 25 THP, C-2'H), 4.0 (m, C-3H), 3.5 (m, W = 10Hz, THP, C-6'H₂), 0.95 (d,

1084

47283K

0078704

J = 6Hz, C-21H₃, 0.23 (s, C-18H₃). IR ν_{\max} 2950 (s), 2900 (sh), 1725 (s), 1640 (s), 1610 (m), 1370 (m), 1350 (m), 1025 (s), cm⁻¹; mass spec. molecular ion m/e = 572; (analysis found: %C, 72.89; H, 7.58; N, 4.78; C₃₅H₄₄O₅N₂ requires: %C, 73.40; H, 7.74; N, 4.89).

- 5 3) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3 β -(t-butylidimethylsilyl)-oxy]-20(S)-formyl-pregna-5(10), 7(E)-diene

Crystalline from CH₂Cl₂/hexane. m.p. 195-197°C; [α]_D = +335° (c = 1.64); ¹Hmr δ 9.52 (d, J = 3Hz, C-22H), 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 4.07 (m, C-3H), 1.07 (d, J = 7Hz, C-21H₃), 0.88 (s, t-butyl), 0.22 (s, C-18H₃), 0.07 (s, Si-CH₃), 0.03 (s, Si-CH₃); IR ν_{\max} 2950 (s), 2900 (sh), 1740 (s), 1650 (s), 1610 (s), 1350 (s), 1090 (s), cm⁻¹; mass spec. molecular ion m/e = 602; (analysis found: %C, 71.57; H, 8.49; N, 4.51; C₃₆H₅₀O₄N₂Si requires: %C, 71.72; H, 8.36; N, 4.65).

- 4) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-20(S)-formyl-3 β -methoxyethoxymethoxy-pregna-5(10), 7(E)-diene

Crystalline from CH₂Cl₂/hexane. m.p. 136-137°C; [α]_D = +327° (c = 0.62); ¹Hmr δ 9.49 (d, J = 3Hz, C-22H), 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 4.87 (s, -OCH₂O-), 4.70 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 4.03 (m, C-3H), 3.7 (m, W = 6Hz, -OCH₂CH₂O-), 3.47 (s, OCH₃), 1.07 (d, J = 7Hz, C-21H₃), 0.22 (s, C-18H₃); IR ν_{\max} 2950 (m), 2900 (sh), 1740 (m), 1650 (s), 1610 (m), 1370 (m), 1350 (m), 1030 (m).

1085

47283K

0078704

Example 3

General procedure for the reduction of the C-20(S)-formyl to the C-20(S)-(hydroxymethyl) derivative.

The aldehyde compound (2.5-3.5g) in benzene (60-90 ml) was added dropwise over a 15-20 min period to NaBH₄ (0.8-1.0g) in ethanol (20-30 ml). After the addition, the excess reducing agent was carefully quenched with dilute aqueous HCl. The mixture was diluted with CH₂Cl₂. Aqueous work-up gave the desired alcohol in essentially quantitative yield. The following compounds have been prepared in this manner.

- 10 1) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3 β -acetoxo-20(S)-[hydroxymethyl]-pregna-5(10), 7(E)-diene

Crystalline from CH₂Cl₂/ether. m.p. 238-240°C; [α]_D = +363° (c = 0.875); ¹Hmr δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 5.07 (m, C-3H), 4.78 and 4.21 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 3.47 (m, W = 14Hz, C-22H₂), 2.05 (s, OAc), 1.0 (broad singlet, C-21H₃), 0.17 (s, C-18H₃); IR ν_{\max} (CHCl₃) 3200 (br), 2950 (m), 2900 (sh), 1750 (m), 1650 (s), 1610 (m), 1380 (m), 1350 (m), cm⁻¹; mass spec. molecular ion m/e = 532.

- 2) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-20(S)-[hydroxymethyl]-3 β -tetrahydroxy-pregna-5(10), 7(E)-diene

Crystalline from CH₂Cl₂/ether. m.p. 170-173°C; [α]_D = +341° (c = 0.58); ¹Hmr δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 4.67 (m, THP, C-2'H), 4.0 (m, C-3H), 3.5 (m, W = 18Hz, C-22H₂, THP, C-6'H₂), 1.0 (broad singlet, C-21H₃), 0.19 (s, C-18H₃); IR ν_{\max} 3600 (br), 2950 (s), 2900 (sh), 1650 (s), 1610 (m),

1086

47283K

0078704

1370 (m), 1350 (m), 1025 (m), cm^{-1} ; mass spec. molecular ion $m/e = 574$; [analysis found: % C 72.96; H, 7.96; N, 4.73; $\text{C}_{35}\text{H}_{46}\text{O}_5\text{N}_2$ requires: % C, 73.14; H, 8.07; N, 4.87).

3) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3E-[t-butylidimethylsilyl]-oxy]-20(S)-[hydroxymethyl]-pregna-5(10), 7(E)-diene

Crystalline from $\text{CH}_2\text{Cl}_2/\text{hexane}$. m.p. 145-148°C; $[\alpha]_D^{25} = +312^\circ$ (c = 1.22); $^1\text{Hnmr}$ δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 4.03 (m, C-3H), 3.4 (m, W = 14Hz, C-22H₂), 1.0 (broad singlet, C-21H₃), 0.88 (s, t-butyl), 0.19 (s, C-18H₃), 0.07 (s, Cl-CH₃); IR ν_{max} 3500 (br), 2950 (s), 2900 (sh), 1640 (s), 1610 (m), 1340 (s), 1250 (s), 1090 (s), cm^{-1} ; mass spec. molecular ion $m/e = 604$; [analysis found: % C, 71.56; H, 8.70; N, 4.47; $\text{C}_{36}\text{H}_{52}\text{O}_4\text{N}_2\text{Si}$ requires: % C, 71.48; H, 8.67; N, 4.63).

15 Example 4

6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3E-acetoxy-20(S)-ethenyl-pregna-5(10), 7(E)-diene

Methyltriphenylphosphonium bromide (60mg, 1.2 eq) was suspended in THF (6 ml). n-Butyl lithium (1.5 M solution, 0.15 ml) was added.

20 To the resulting orange-coloured solution, the 3E-acetoxy aldehyde from Example 2(f) (1) (100 mg) in benzene (6 ml) was added quickly. After a further 10 min, water was added and the mixture extracted with CH_2Cl_2 . Acid work-up followed by purification by plc gave 75 mg (75%) of the title product.

25 Crystalline from $\text{CH}_2\text{Cl}_2/\text{ether}$. m.p. 173-175°C; $[\alpha]_D^{25} = +386^\circ$ (c = 0.86);

1087

47283K

0078704

$^1\text{Hnmr}$ δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 5.6-4.8 (m, C-3H, 22H, 23H₂), 4.78 and 4.21 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 2.03 (s, OAc), 0.95 (d, J = 7Hz, C-21H₃), 0.17 (s, C-18H₃); IR ν_{max} 2950 (m), 1740 (s), 1650 (s), 1610 (m), 1370 (s), 1350 (s), 1260 (s), 1230 (s), cm^{-1} ; mass spec. molecular ion $m/e = 528$; [analysis found: % C, 75.03; H, 7.72; N, 5.21; $\text{C}_{33}\text{H}_{40}\text{O}_4\text{N}_2$ requires: % C, 74.97; H, 7.63; N, 5.30).

Example 5

10 (a) Preparation of isobutylene epoxide

To methylallyl chloride (200 ml), 186g) cooled in an ice bath was added 80% H_2SO_4 (H_2SO_4 , 95%, 109 ml; H_2O , 40 ml, 1 eq) over a 30 min period. The temperature of the mixture was maintained between 5-10°C.

After a further 3 hr the mixture was added to ice and diluted to a total 15 volume of approx. 100 ml. The layers were separated and the organic residue distilled to remove the by-product 8,8-dimethylvinyl chloride and unreacted starting material. These materials are removed below 80°C. The darkly coloured distillation residue is 1-chloro-2-methylpropan-2-ol (128a) δ 3.47 (s, 2H), 2.97 (s, 1H, exchanges with D_2O), 1.32 (s, 6H). This material was used without further purification.

To a 500 ml round bottom flask containing KGI (200g) in water (125 ml) at 80°C and fitted with a mechanical stirrer and condenser, was added dropwise the crude chlorohydrin. The crude epoxide distilled directly from the reaction mixture. Redistillation gave isobutylene 25 epoxide (48g, 35%) b.p. 51°C (lit. 120-52°C); $^1\text{Hnmr}$ δ 2.6 (s, 2H), 1.33 (s, 6H).

1088

47283K

0078704

(b) 4-bromo-2-methyl-2-hydroxy-butane

To ethyl 3-bromo-propionate (21g) in ether (150 ml) at 0°C was added methylmagnesium bromide (3 M soln. in ether, 125 ml, excess) dropwise. After the addition was complete, the mixture was stirred for a further

5 2 hrs at room temperature. After cooling again to 0°C, the mixture was carefully quenched with NH_4Cl (30g) in water (200 ml). The mixture was separated and the ether layer washed with water until neutral, followed by brine, and dried. Evaporation gave the crude bromo-alcohol (227a) J_{Hnmr} δ 3.53 (t, J = 9Hz, 2H), 2.93 (s, 1H, exchanges with D_2O), 2.07 (t, J = 9Hz, 2H), 1.27 (s, 6H); [lit. 1.71 3.54 (t, J = 8.5Hz, 2H), 2.65 (s, broad, 1H), 2.10 (t, J = 8.5Hz, 2H), 1.26 (s, 6H)].

(c) 4-bromo-2-methyl-2-(triethylsiloxy)-butane

Half of the crude bromide from (b) above in ether (50ml) containing pyridine (5 ml), imidazole (10g) and triethylsilylchloride (10 ml) was stirred for 2 days at room temperature. Water was added. Acid work-up followed by chromatography gave 11g (62% from the propionate) of the desired compound, homogeneous by tlc. J_{Hnmr} δ 3.52 (m, 2H), 2.03 (m, 2H), 1.25 (s, 6H), 1.2-0.2 (m, 15H); IR ν_{max} (thin film) 3000 (s), 2950 (sh), 1460 (m), 1420 (m), 1380 (m), 1365 (m), 1230 (s), 1195 (s), 1170 (m), 1100 (s), 1040 (s), 1010 (s), 965 (m), 840 (w), 740 (s), 720 (s), cm^{-1} .

(d) 3-Methyl-2-buten-1-yl-triphenylphosphonium bromide

The bromide from (c) above (1g) and triphenylphosphine (0.9g) in benzene (4 ml) was thoroughly degassed, and then heated to reflux. After 3 days, the insoluble material was filtered off to give 1.2g (85%) of phosphonium salt (228). Recrystallised from $\text{CH}_2\text{Cl}_2/\text{EtOAc}$. m.p. 234-238°C (lit. 119b)

1089

47283K

0078704

236-239°C); J_{Hnmr} δ 8.17-7.67 (m, 15H, aryl), 5.18 (m, $\text{W} = 18\text{Hz}$), 4.73-4.2 (m, 2H), 1.67 (d, J = 5Hz, 3H), 1.31 (d, J = 5Hz, 3H); IR ν_{max} 2900 (w), 1590 (w), 1490 (m), 1435 (s), 1110 (s), cm^{-1} .

(e) Methyldiphenylphosphine oxide

5. Methyltriphenylphosphonium bromide (5g) was refluxed overnight with KOH (5g) in water (70 ml). The mixture was allowed to cool to room temperature and then extracted (3x) with CH_2Cl_2 . The organic layer was washed with brine, dried and the solvent removed to give the crude solid product (3.5g) in essentially quantitative yield. Recrystallised from 10 acetone. m.p. 113-114°C (lit. 132 109-111°C); J_{Hnmr} δ 8.0-7.3 (m, 10H, aryl), 2.03 (d, J = 13Hz, 3H); IR ν_{max} 1440 (s), 1175 (s), cm^{-1} ; mass spec. molecular ion $m/e = 216$.

(f) 3-Hydroxy-3-methylbut-1-yl-diphenylphosphine oxide

15. Methyldiphenylphosphine oxide (1.5g) was suspended in ether (20 ml) at 0°C. BuLi (1.2 eq) was slowly added, and an orange coloured solution formed. To this was added isobutylene epoxide (0.8 ml, 1.3 eq). After approx. 15 min, the mixture was carefully quenched with water. This mixture was extracted with CH_2Cl_2 (2x) and the organic layer was washed with 4% aqueous HCl/brine and concentrated. The resulting yellow, oily product was dissolved in a water-ether mixture and the layers separated. The ether layer was washed once with water, and the combined aqueous fractions extracted with CH_2Cl_2 (3x). The organic layer was washed with brine and dried. The solvent was removed and the resulting colourless oil was taken up in benzene and refluxed through a soxhlet containing

1090

47283K

0078704

CH₂ for 2hr. The solvent was removed to give crude title

compound (1.4g, 70%) as an oil. ¹Hmr δ 8.0-7.3 (m, 10H, aryl), 2.5 (m, W = 34Hz, 2H), 1.83 (m, W = 32Hz, 3H), 1.23 (s, 6H); IR ν_{max} (CCl₄) 3500 (m), 2950 (m), 1440 (s), cm⁻¹.

5 (g) 3-tetrahydropyranyloxy-3-methylbut-1-yl-diphenylphosphine oxide

The phosphine oxide from (f) above (1.4g) was dissolved in dihydropyran

(20ml) and benzene (5ml). p-Toluenesulphonic acid (10mg) was added. After 20hr, the mixture was concentrated, added to CH₂Cl₂ and washed with 5% aqueous NaHCO₃/brine and dried. Evaporation of the solvent gave the crude product

10 (1.8g) essentially quantitatively as a solid. Recrystallised from acetone.

m.p. 146-148°C; ¹Hmr δ 8.0-7.3 (m, 10H, aryl), 4.67 (m, W = 6Hz, THP, C-2'H), 3.67 (m, W = 36Hz, THP, C-6'H₂), 1.23 (s, 6H); IR ν_{max} 2950 (m), 1440 (m), 1180 (s), cm⁻¹; (analysis found: % C, 70.80; H, 7.73; P, 8.54; C₂₂H₂₉O₃P requires % C, 70.96; H, 7.85; P, 8.32).

15 (h) Preparation of the lithium bromide adduct of the betaine

To methyltriphenylphosphonium bromide (2.898g) suspended in ether (50 ml) cooled to 0°C was added butyl lithium (2.03 M soln.; 4 ml).

Isobutylene epoxide (1.0ml, 1.25 eq) was added and some insoluble material instantly formed. After stirring for 15 min, the reaction

20 mixture was allowed to settle and the supernatant liquid was removed.

The resulting solid was suspended in ether and transferred to two centrifuge tubes, and spun. The ether was removed. This process was

repeated until the ether washing were colourless (usually 4x). The

colourless solid material was dried to give the Li-Br adduct of the

5 betaine (1.5g) 42%. Beilstein and lithium ion positive, flame tests.

IR ν_{max} (nujol) 3500 (br), 3000 (s), 1440 (s), cm⁻¹.

1091

47283K

0078704

(i) [3-(triethylsilyloxy)-3-methylbut-1-yl]-triphenylphosphonium tetraphenyl borate

To methyltriphenylphosphonium bromide (3g) suspended in THF (40 ml)

was added phenyl lithium (1 eq; 6 ml of a 1.5 M soln.). After 15 min

5 isobutylene epoxide (1 ml, 1.25 eq) was added followed, after a further

5 min, by a second addition of phenyl lithium (1 eq). To this mixture

was added benzophenone (1g; approx. 0.3 eq). After stirring for 20 min,

the reaction was quenched with 48% aqueous HBr until just acidic

(litmus paper). The organic solvent was removed on a rotary eva-

10 porator, water was added and the aqueous layer washed with ether,

and the layers separated. The water was removed (rotary evaporator)

and the resulting oil taken up in CH₂Cl₂. Aqueous work-up gave the

phosphonium salt (226) (3.1g) 58% as an oil. ¹Hmr δ 8.17-7.67 (m,

15H, aryl), 5.37 (broad s, -OH), 3.8 (m, W = 32Hz, C-1H₂), 1.8 (m,

15 W = 22Hz, C-2H₂), 1.28 (s, (-CH₃)₂); IR ν_{max} (CHCl₃) 3450 (s), 3000

(s), 1590 (sh), 1440 (s), cm⁻¹.

(j) Silylation

To the phosphonium salt from (i) above (3.7g) in CH₂Cl₂ (70ml) was added

imidazole (3.4g) followed by triethylsilylchloride (5 ml). After 40

20 hr stirring at room temperature, water was added and the mixture di-

luted with CH₂Cl₂. The CH₂Cl₂ solution after an acid work-up was

evaporated and the oily residue partitioned between water and hexane/

ether. The water was evaporated and the residue taken up in CH₂Cl₂

which was washed with brine and dried to give on evaporation the salt

25 (226b) (3.6g, 77%) as an oil.

1092

47233K

0078704

(k) Anion exchange

To the phosphonium salt from (j) above (3.6g) in 95% ethanol (50ml) was added dropwise, with stirring, a solution of sodium tetraphenyl borate

(2.5g; 1.1 eq) in water (20 ml). An oily residue is formed which solid-

5 dries on continued stirring. Filtration gives the phosphonium tetraphenyl borate salt (4.78g, 92%) as a white, amorphous, non-hygroscopic solid which may be recrystallized from acetone/hexane/ethanol. m.p. 150-151°C; $^1\text{H NMR}$ δ

(acetone- d_6) 8.2-6.8 (m, 35H, aryl), 3.53 (m, W=34Hz, C-11 $_2$), 1.8 (m, W=24Hz, C-21 $_2$), 1.33 (s, (-CH $_3$) $_2$), 1.25-0.5 (m, 15H, -SiEt $_3$); IR ν_{max} 3100 (s).

10 2950 (s), 1580 (m), 1490 (s), 1440 (s), 1110 (s), 1020 (s). cm^{-1} ;

[analysis found: % C, 81.41; H, 7.73; P, 3.93; $\text{C}_{53}\text{H}_{60}\text{P}_2\text{Si}_3$ requires:

% C, 81.31; H, 7.73; P, 3.96.

(1) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3 β -acetoxy-25-hydroxy-cholesta-5(10), 7(E), 22(E)-triene

15

Method A

To methyltriphenylphosphonium bromide (2.898g) suspended in THF (32ml) at 0°C was added butyl lithium (2.03 M, 4 ml). Iso-butylene

epoxide (720 μl , 1 eq) was slowly added. After a further 15 min,

butyl lithium (4 ml) was added. To 3 ml of this solution was added

20 the aldehyde from Example 2(f) (1) (300mg) in benzene (10ml). The red colour

was quickly discharged. Water was added and the mixture extracted with CH_2Cl_2 . After acid work-up the major product was isolated by plc to give the title compound (105 mg, 31%).

Method B

25 The betaine from (h) above (628mg) was suspended in ether (15ml) and THF (10ml). Butyl lithium was added dropwise until a stable colour was formed and then (0.75ml, 2 eq for steroid, 1

1093

47283K

1094

47283K

0078704

eq for P compound) was added. To this mixture was added the aldehyde from Example 2(f) (1) (400mg) in benzene (6ml) (approx. 5 min). After the addition, water was added and the mixture extracted with CH_2Cl_2 . Work-up as above gave the title

5 compound (155mg, 34%).

Method C

The phosphonium salt from (h) above (280mg, 1.5 eq) was dissolved in THF (15 ml) at 0°C. Phenyl lithium (3 eq) was added. The aldehyde (206a)

(150mg, 1 eq) in benzene (6 ml) was added quickly. Tlc showed no

10 change during 30 min and so water was added. Work-up as above, and

isolation by plc gave the title product (80mg, 47%). Crystalline from CH_2Cl_2 /ether. m.p. 175-177°C; $[\alpha]_D^{20} = +347^\circ$ (c=0.83); $^1\text{H NMR}$ δ 8.3 (m,

W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz,

C-7H), 5.27 (m, W = 10Hz, C-3H, 22H, 23H), 4.78 and 4.21 (an AB system,

15 J = 18Hz, C-19H $_2$), 4.75 (d, J = 10Hz, C-6H), 2.03 (s, OAc), 1.15 (s,

C-26H $_3$, 27H $_3$), 0.97 (d, J = 7Hz, C-21H $_3$), 0.17 (s, C-18H $_3$); IR ν_{max}

3800 (m), 2950 (s), 2900 (sh), 1750 (s), 1650 (s), 1610 (m), 1370 (s),

1350 (s), 1240 (s), 965 (m), cm^{-1} ; mass spec. molecular ion m/e = 600;

(analysis found: % C, 73.94; H, 8.17; N, 4.59; $\text{C}_{37}\text{H}_{46}\text{O}_5\text{N}_2$ requires: %

20 C, 73.97; H, 8.05; N, 4.66.

(m) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3 β -acetoxy-25-hydroxy-cholesta-5(10), 7(E), 22(Z)-triene

To the phosphonium salt from (i) above (1.9g) in THF (30ml) was added phenyl lithium (1.5 M soln., 1.7 ml, 1 eq). After a few minutes, the

25 aldehyde (206a) (1g) in benzene (35 ml) was added dropwise over about

1 min. After a further 3 min, water was added and the mixture diluted

with CH_2Cl_2 and given an acid work-up. The reaction was repeated as

0078704

above and the combined products chromatographed to yield 2.12g (78%) of a crude, yellow coloured product.

- The above mixture (1.4g) was treated with $\text{AcOH:H}_2\text{O:THF}$ (8:1:1) (10 ml) for 1.5 hr. Dilution with CH_2Cl_2 followed by aqueous work-up, chromatography and crystallisation gave 1g of product (85%). Further recrystallisation from CH_2Cl_2 /ether, indicated the major component to have the following characteristics. m.p. 182-184°C; $[\alpha]_D^{20} = +339^\circ$ (c = 0.84); ^1Hmr δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 5.27 (m, W = 12Hz, C-3H, 22H, 23H), 4.78 and 4.21 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 2.03 (s, OAc), 1.17 (s, C-26H₃, 27H₃), 0.9 (d, J = 7Hz, C-21H₃), 0.17 (s, C-18H₃); IR ν_{max} 3650 (m), 2950 (s), 2900 (sh), 1750 (s), 1650 (s), 1610 (m), 1370 (s), 1350 (s), 1240 (s), cm^{-1} ; mass spec. molecular ion m/e = 600; (analysis found: % C, 74.10; H, 8.15; N, 4.47; $\text{C}_{37}\text{H}_{48}\text{O}_4\text{N}_2$ requires: % C, 73.97; H, 8.05; N, 4.66).

10 6(R), 19-(N,N'-phthalhydrazido)-9,10-seco-3 α ,25-dihydroxy-cholesta-5(10), 7(E)-diene

The unsaturated side chain compound from (11) above (450mg) in benzene (5ml) and ethanol (5ml) containing NaHCO_3 (100mg) and 5% Pt/C (150mg) was stirred under a hydrogen atmosphere for 24 hr. The mixture was filtered through celite and the solvent removed. To the residue, in benzene (10 ml), was added NaOH in methanol (1.25 M soln, 2 ml) and the mixture stirred for 20 min at room temperature. Acid work-up and crystallisation from CH_2Cl_2 /ether afforded 380 mg (91%) of the title side chain saturated diol. m.p. 174-177°C; $[\alpha]_D^{20} = +408^\circ$ (c = 0.825); ^1Hmr δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 4.78 and 4.22 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H),

1095

47233K

0078704

4.11 (m, C-3H), 1.22 (s, C-26H₃, 27H₃), 0.87 (broad singlet, C-21H₃), 0.18 (s, C-18H₃); IR ν_{max} 3550 (s), 2950 (s), 2900 (sh), 1650 (s), 1610 (m), 1370 (s), 1350 (s), cm^{-1} ; (analysis found: % C, 74.65; H, 8.66; N, 5.06; $\text{C}_{35}\text{H}_{48}\text{O}_4\text{N}_2$ requires: % C, 74.96; H, 8.63; N, 5.00).

5 Example 6

General procedure for the conversion of the phthalazine-1,4-dione adduct to the corresponding 5(E), 7(E), 10(E), 10(19)-triene system of the calciferol.

The adduct (200-600mg) was refluxed overnight, under argon in ethanol (10 (10 ml) and hydrazine (3 ml). After cooling to room temperature, the solvents were removed under reduced pressure and the resulting solid taken up in water (30 ml) and CH_2Cl_2 (30 ml). To this two-phase system under argon was added dianisyltellurium oxide (150-450mg), K_2CO_3 (6g) and 1,2-dibromotetrachloroethane (3g), and the mixture stirred for approx. 15.5 hr (tlc control). After acid work-up the mixture was chromatographed through silica gel (12g) and the product removed from traces of tellurium oxidant by plc to give the desired vitamin D compound in 85-93% yield.

1) 9,10-seco-3 α ,25-dihydroxy-cholesta-5(E), 7(E), 10(19)-triene

Prepared from the adduct (240b) (200mg) as described above, to give 20 (131mg (92%). Solid from ether/hexane. m.p. 79-81°C; $[\alpha]_D^{20} = +160^\circ$ (c = 0.735); UV λ_{max} 273nm (21500); ^1Hmr δ 6.5 and 5.83 (ABq, J = 11Hz, C-6H, 7H), 4.97 (s, C-19H), 4.67 (s, C-19H), 3.85 (m, W = 14Hz, C-3H), 1.22 (s, C-26H₃, 27H₃), 0.95 (broad singlet, C-21H₃), 0.55 (s, C-18H₃); IR ν_{max} 3400 (m), 2950 (s), 1620 (w); mass spec. molecular ion m/e = 25400; (analysis found % C, 77.50; H, 10.99; $\text{C}_{27}\text{H}_{44}\text{O}_2$ requires: % C, 80.94; H, 11.07; $\text{C}_{27}\text{H}_{44}\text{O}_2\cdot\text{H}_2\text{O}$ requires: % C, 77.46; H, 11.07).

1096

47233K

0078704

2) 3 β -(3',5'-dinitrobenzoate) ester

The above crude calciferol (1) (125mg) in pyridine (5ml) was treated with 3,5-dinitrobenzoyl chloride (85mg, 1.1eq). Water was added and the mixture diluted with ether. After acid work-up, the ester was isolated by plc (129mg, 70%). Crystalline from ether/hexane. m.p. 105-107°C; $[\alpha]_D^{25} = +168^\circ$ (c = 0.97); $^1\text{Hnmr}$ δ 9.13 (m, 3H, aryl), 6.62 and 5.82 (ABq, J = 11Hz, C-6H, 7H), 5.3 (m, W = 14Hz, C-3H), 5.07 (s, C-19H), 4.77 (s, C-19H), 1.23 (s, C-26H₃, 27H₃), 0.93 (broad singlet, C-21H₃), 0.43 (s, C-18H₃); IR ν_{max} 3550 (m), 2950 (s), 2900 (sh), 1750 (s), 1640 (w), 1550 (s), 1350 (s), 1275 (s), cm^{-1} ; (analysis found: % C, 68.62; H, 7.85; N, 4.65; C₃₄H₄₆N₂O₇ requires: % C, 68.66; H, 7.80; N, 4.71).

Example 7(a) 9,10-seco-3 β ,25-dihydroxy-cholesta-5(Z),7(E),10(19)-triene

A solution of the 5,6-*trans* compound from Example 6(1) (126mg) in benzene (30 ml) containing triethylamine (2 drops) and anthracene (25mg) was thoroughly degassed. A Hanovia lamp (number 654A36) was placed such that the outside of the water cooled jacket was 15cm from the reaction vessel. The mixture was irradiated for 25 min and the title 5,6-*cis* compound isolated by plc (93mg, 74%). Crystalline from acetone/water. m.p. 98-100°C (lit. 174 95-100°C); $[\alpha]_D^{25} = +77^\circ$ (c = 0.26); UV λ_{max} 262nm (19060); $^1\text{Hnmr}$ δ 6.25 and 6.1 (ABq, J = 11Hz, C-6H, 7H), 5.05 (s, C-19H), 4.83 (s, C-19H), 3.9 (m, W = 18Hz, C-3H), 1.27 (s, C-26H₃, 27H₃), 0.95 (broad singlet, C-21H₃), 0.55 (s, C-18H₃); IR ν_{max} 3500 (s), 2950 (s), 2900 (sh), 1640 (w), 1480 (m), 1380 (m), 1055 (s), cm^{-1} ; (analysis: C₂₇H₄₄O₂.H₂O requires: %C, 77.46; H, 11.08; found: %C, 77.29; H, 11.08.

The melting point of an authentic sample supplied by Roussel Uclaf, Inc. (Romainville, France) did not depress on mixing.

1097

47283K

0078704

(b) 3-(3',5'-dinitrobenzoate) ester

Prepared as previously described in Example 6(2). Crystalline from ether/hexane. m.p. 149-150°C (lit. 172 147-148°C); $[\alpha]_D^{25} = +90^\circ$ (c = 0.6); (analysis: C₃₄H₄₆N₂O₇ requires: % C, 68.66; H, 7.80; N, 4.71; found: % C, 68.94; H, 7.80; N, 4.52).

Example 850₂ adducts of 9,10-seco-3 β -hydroxy-ergosta-5(Z),7(E),10(19),22(E)-tetraene

Sulphur dioxide was slowly passed through a well-stirred mixture of benzene (100 ml) and water (50 ml) containing ergocalciferol (5g), for a total of 3.5 hr. After this time, air was passed through the mixture for approx 20 min. Ether and brine were added and the layers separated. Aqueous work-up gave the known sulphur dioxide adducts (172a, 173a) which were used without further purification.

15 Example 9(a) 9,10-seco-3 β -(triethylsilyloxy)-ergosta-5(E),7(E),10(19),22(E)-tetra-ene.

To the 3 β -alcohol corresponding to the title compound (4.3g) in CH₂Cl₂ (50 ml) was added imidazole (4g) followed by triethylsilylchloride (3ml). After a few minutes, water was added and the organic layer washed with water/brine and dried. The required silyl ether was isolated essentially quantitatively after chromatography as an oil. UV λ_{max} 274nm; $^1\text{Hnmr}$ δ 6.45 and 5.87 (ABq, J = 11Hz, C-6H, 7H), 5.2 (m, W = 9Hz, C-22H, 23H), 4.92 (s, C-19H), 4.63 (s, C-19H), 3.82 (m, W = 18Hz, C-3H),

1098

47283K

0078704

- (b) 9,10-seco-1a-hydroxy-3a-(triethylsilyloxy)-ergosta-5(E), 7(E), 10(19), 22(E)-tetraene

N-Methylmorpholine N-oxide (NMO) (6.3g) was stirred with anhydrous $MgSO_4$ in CH_2Cl_2 (50 ml) for 30 min. Selenium dioxide (1.3g) was stirred in methanol (50 ml) for 45 min and warmed to reflux. The above CH_2Cl_2 mixture was filtered into a solution of the 5,6-*trans*-ergocalciferol derivative from (a) above (5.5g) in 1,2-dichloroethane (50ml). This mixture was warmed to reflux and then the hot methanol mixture added, and refluxing of the whole continued for a further 35 min. The heat source was removed and the mixture diluted with CH_2Cl_2 . Aqueous work-up followed by chromatography through silica gel (40g) gave 2.66g (47%) of the title compound as an oily product. UV λ_{max} 274nm, $^1H_{NMR}$ δ 6.57 and 5.90 (ABq, J=11Hz, C-6H, 7H), 5.25 (m, W=9Hz, C-22, 23H), 5.08 (s, C-19H), 4.98 (s, C-19H), 4.65-3.92 (m, C-1H, 3H).

- 15 (c) 9,10-seco-1a,3a-dihydroxy-ergosta-5(E), 7(E), 10(19), 22(E)-tetra-ene

The silyl ether from (b) above (460mg) in THF (10ml) was stirred for 30 min with tetrabutylammonium fluoride (460mg). The mixture was diluted with CH_2Cl_2 and after aqueous work-up, the title diol was purified by plc to give 305mg (84%). Crystalline from ether/hexane. m.p. 103-105°C; $[\alpha]_D^{20} = +172^\circ$ (c = 0.58); UV λ_{max} 272nm (22600); $^1H_{NMR}$ δ 6.38 and 5.82 (ABq, J = 11Hz, C-6H, 7H), 5.18 (m, W = 9Hz, C-22H, 23H), 4.9 (m, W = 9Hz, C-19H₂), 4.53-3.77 (m, C-1H, 3H), 0.57 (s, C-18H₃); IR ν_{max} 3500 (s), 2950 (s), 2900 (sh), 1640 (w), 1460 (m), 1375 (m), 1050 (s), 1030 (s), cm^{-1} ; mass spec. molecular ion m/e = 412; (analysis found: % C, 79.57; H, 10.71; $C_{28}H_{44}O_2$ requires: % C, 81.50; H, 10.79; $C_{28}H_{44}O_2 \cdot \frac{1}{2}H_2O$ requires: % C, 79.76; H, 10.76).

1099

47283K

0078704

- (d) 9,10-seco-1a-hydroxy-3a-triethylsilyloxy-ergosta-5(Z), 7(E), 10(19), 22(E)-tetra-ene

The 5,6-*trans* compound from (b) above (600mg) in benzene (30ml) containing phenazine (120mg) and triethylamine (few drops) was photoisomerised as above for 30 min to give 400mg (66%) of the title 5,6-*cis* vitamin. UV λ_{max} 263nm; $^1H_{NMR}$ δ 6.38 and 6.08 (ABq, J = 11Hz, C-6H, 7H), 5.23 (m, W = 10Hz, C-19H, 22H, 23H), 5.0 (s, C-19H), 4.6-3.92 (m, C-1H, 3H).

- (e) 9,10-seco-1a,3a-dihydroxy-ergosta-5(Z), 7(E), 10(19), 22(E)-tetra-ene

The silyl ether derivative from (d) above (200mg) was stirred at room temperature in THF (10 ml) with N-Bu₄NF (1 M soln. in THF, 2 ml) for about 30 min. Dilution with CH_2Cl_2 and aqueous work-up followed by purification by plc gave 129mg (82%). Crystalline from ether/hexane gave the title compound. m.p. 141-143°C (lit. 138-140°C); $[\alpha]_D^{20} = +34^\circ$ (c = 0.645); UV λ_{max} 264nm (19100); $^1H_{NMR}$ δ 6.35 and 6.05 (ABq, J = 11Hz, C-6H, 7H), 5.16 (m, W = 14Hz, C-19H, 22H, 23H), 4.98 (s, C-19H), 4.6-3.85 (m, C-1H, 3H), 0.55 (s, C-18H₃); IR ν_{max} 3500 (s), 2950 (s), 2900 (sh), 1640 (w), 1460 (m), 1370 (m), 1060 (s), cm^{-1} ; mass spec. molecular ion m/e = 412; (analysis: $C_{28}H_{44}O_2$ requires: % C, 81.50; H, 10.75; O, 7.76; found: % C, 81.39; H, 10.60).

Example 10

- (a) 9,10-seco-3a-acetoxy-1a-benzoyloxy-ergosta-5(E), 7(E), 10(19), 22(E)-tetra ene

The 1a-hydroxy-3a-triethylsilyloxy-compound from Example 9(b) (2g) was treated with benzoyl chloride (2 ml) in pyridine (25 ml). After 30 min water was added and the mixture diluted with ether. After acid work-up, the

1100

47283K

solvent was removed and the resulting oil stirred overnight in THF:H₂O: AcOH; 8:1:3 (36ml). After dilution with ether and aqueous work-up, the crude benzoate-alcohol was taken up in benzene (40 ml). Triethylamine (7 ml), acetic anhydride (3 ml) and 4-dimethylaminopyridine (15mg) were added. After 30 min, water was added and the mixture diluted with ether. Acid work-up and chromatography through silica (10g) gave 1.76g (83%) of the title acetate-benzoate as an oil. ¹Hnmr δ 8.05 (m, W = 12Hz, 2H, aryl), 7.5 (m, W = 10Hz, 3H, aryl), 6.58 (d, J = 11Hz, C-6H), 5.88 (m, W = 16Hz, C-1H, 7H), 5.15 (m, W = 10Hz, C-3H, 19H₂, 22H, 23H), 2.05 (s, OAc), 0.57 (s, C-18H₃).

- 5

(b) 6(R),19-[N,N'-phthalhydrazido]-9,10-seco-1α-benzoyloxy-3β-acetoxy-ergosta-5(10), 7(E), 22(E)-triene

- To a well-stirred suspension of phthalhydrazide (2g) in CH₂Cl₂ (200 ml) at 0°C, containing the vitamin from (a) above (2g), was added dropwise a solution of Pb(OAc)₄ (4g) in CH₂Cl₂ (20 ml) and acetic acid (1 ml). After consumption of starting material (tlc control), the excess phthalhydrazide was removed by filtration. Aqueous work-up and chromatography gave 1.4g (52% from 248b) of a 95:5 mixture of (250) and the presumed 6(S) isomer. Crystallisation from CH₂Cl₂/hexane gave pure title compound. m.p. 211-213°C; [α]_D²⁰ = +295° (c = 0.83); ¹Hnmr δ 8.5-7.3 (m, 9H, aryl), 5.95 (m, W = 14Hz, C-1H, 7H), 5.28 (m, C-3H), 5.17 (m, W = 10Hz, C-22H, 23H), 4.92 and 4.37 (an AB system, J = 18Hz, C-19H₂), 4.8 (m, C-6H), 2.05 (s, OAc), 0.17 (s, C-18H₃): IR ν_{max} 2950 (s), 2900 (sh), 1750 (s), 1720 (s), 1640 (s), 1610 (m), 1265 (s), 1245(s), cm⁻¹; mass spec. molecular ion m/e = 718; [analysis found % C, 75.26; H, 7.54; N, 3.82; C₄₅H₅₄O₆N₂; requires: % C, 75.18; H, 7.57; N, 3.90).

Example 11

(a) SO₂ adducts of 9,10-seco-3β-(t-butylidimethylsilyloxy)-ergosta-5(E), 7(E), 10(19), 22(E)-tetraene

The crude mixture of sulphur dioxide adducts of ergocalciferol

- 5 (prepared from 5g of ergocalciferol as described previously), in CH₂Cl₂ (40 ml), containing imidazole (4g) was stirred with t-butylidimethylsilyl chloride (3.5g). After 1.5 hr, the reaction was worked-up as described previously to give, after chromatography, 4.8g (66%, from ergocalciferol) of the title compound as an oil epimeric at C-6. ¹Hnmr δ 5.22 (m, W = 9Hz, C-22H, 23H), 4.64 (m, W = 10Hz, C-6H, 7H), 4.02 (m, W = 16Hz, C-3H), 3.67 (broad s, C-19H₂), 0.91 (s, t-Bu), 0.68 + 0.59 (2xs, C-18H₃), 0.07 s, [(Si-CH₃)₂].

(b) SO₂ adducts of 9,10-seco-3β-triethylsilyloxy-ergosta-5(E), 7(E), 10(19), 22(E)-tetraene

- 15 The crude mixture of sulphur dioxide adducts of ergocalciferol (prepared from 5g of ergocalciferol as described previously), in CH₂Cl₂ (40 ml), containing imidazole (4g) was stirred with triethylsilylchloride (3.5 ml). After about 30 min, the reaction was worked up as described previously to give, after chromatography, 5.3g (74% from ergocalciferol) of (210b) as an oil. ¹Hnmr δ 5.22 (m, W = 9Hz, C-22H, 23H), 4.64 (m, W = 10Hz, C-6H, 7H), 4.02 (m, W = 16Hz, C-3H), 3.67 (broad s, C-19H₂).

(c) SO₂ adducts of 9,10-seco-3β-(t-butylidimethylsilyloxy)-20(S)-formyl-pregna-5(E), 7(E), 10(19)-triene

- 25 The vitamin D₂ adduct from (b) above (4.7g) was treated with ozone as described in the general procedure to give, after chromatography,

3.25g (78%) of the aldehyde (211a). ^1Hmr δ 9.39 (m, C-22H), 4.66 (m, W = 16Hz, C-6H, 7H), 4.0 (m, W = 16Hz, C-3H), 3.66 (broad s, C-19H₂), 1.15 (d, J = 6Hz, C-21H₃), 0.89 (s, t-Bu), 0.71 + 0.62 (2xs, C-18H₃), 0.05 s, [(Si-CH₃)₂]; IR ν_{max} (thin film) 2950 (s), 2900 (sh), 1720 (s), 1660 (w), 1460 (m), 1305 (s), 1250 (s), 1150 (m), cm^{-1} .

(d) Similarly prepared in 82% yield from (b) above was the SO_2 adducts of 9,10-seco-3 β -(triethylsilyloxy)-20(S)-formyl-pregna-5(E), 7(E), 10(19)-triene

^1Hmr δ 9.57 (m, C-22H), 4.67 (m, W = 12Hz, C-6H, 7H), 3.97 (m, W = 16Hz, C-3H), 3.65 (broad s, C-19H₂), 1.15 (d, J = 6Hz, C-21H₃); IR ν_{max} (thin film) 2950 (s), 2900 (sh), 1735 (s), 1660 (w), 1460 (m), 1380 (m), 1310 (s), 1150 (m), cm^{-1} .

10 Example 12

Example 12

(a) SO_2 adducts of 9,10-seco-3 β -(t-butylidimethylsilyloxy)-20(S)-[hydroxymethyl]-pregna-5(E), 7(E), 10(19)-triene

15 The aldehyde corresponding to the title compound (3.1g) was reduced as described in the general procedure to the title compound in essentially

quantitative yield. ^1Hmr δ 4.63 (m, W = 12Hz, C-6H, 7H), 4.02 (m, W = 16Hz, C-3H), 3.80-3.28 (m, C-19H₂, 22H₂), 1.05 (d, J = 6Hz, C-21H₃), 0.87 (s, t-Bu), 0.68 + 0.58 (2xs, C-18H₃), 0.05 [s, (Si-CH₃)₂]; IR ν_{max} (thin film) 3550 (br), 2950 (s), 2900 (sh), 1660 (w), 1475 (m), 1350 (s), 1275 (s), 1155 (m), cm^{-1} .

(j) Similarly prepared in greater than 90% yield was the SO_2 adducts of 9,10-seco-3 β -(triethylsilyloxy)-20(S)-[hydroxymethyl]-pregna-5(E), 7(E), 10(19)-triene

^1Hmr δ 4.63 (m, W = 12Hz, C-6H, 7H), 3.93 (m, W = 16Hz, C-3H), 3.77 - 3.17 (m, C-19H₂, 22H₂); IR ν_{max} (thin film) 3550 (br), 2950 (s), 2900 (sh), 1660 (w), 1460 (m), 1380 (m), 1305 (s),

1240 (m), 1155 (m), cm^{-1} .

(2) 9,10-seco-3 β -(t-butylidimethylsilyloxy)-20(S)-[hydroxymethyl]-pregna-5(E), 7(E), 10(19)-triene

Adducts of (1) above (3g) was stirred in refluxing methanol (50 ml) 5 containing NaHCO_3 (3g) for 2.5 hr. Work-up as described above gave 2.36g (90%) of the calciferol. UV λ_{max} 274nm; ^1Hmr δ 6.47 and 5.87 (ABq, J = 11Hz, C-6H, 7H), 4.92 (s, C-19H), 4.65 (s, C-19H), 4.1-3.15 (m, C-3H, 22H₂), 1.06 (d, J = 5Hz, C-21H₃), 0.9 (s, t-Bu), 0.58 (s, C-18H₃), 0.07 s, [(Si-CH₃)₂].

10 (3) Similarly prepared in 47% yield from the adducts of (1) above after chromatography was 9,10-seco-3 β -(triethylsilyloxy)-20(S)-[hydroxymethyl]-pregna-5(E), 7(E), 10(19)-triene (267d). UV λ_{max} 273nm; ^1Hmr δ 6.43 and 5.7 (ABq, J = 11Hz, C-6H, 7H), 4.9 (s, C-19H), 4.6 (s, C-19H), 4.03-3.13 (m, C-3H, 22H₂).

Example 13

9,10-seco-3 β -hydroxy-20(S)-[hydroxymethyl]-pregna-5(E), 7(E), 10(19)-triene

Method A

The phthalazine adduct from Example 3(1) (200mg) was treated with 20 hydrazine, followed by oxidation as described in the general procedure to give the title product (105mg; 85%).

Method B

The phthalazine adduct from Example 3(3) (250mg) was similarly converted to give the t-butylidimethylsilyl ether of the title 25 product (166mg, 90%). This material in refluxing THF (10ml) was

stirred with $n\text{-Bu}_4\text{NF}$ (1 N soln in THF, 2 ml) for 1 hr. Dilution with CH_2Cl_2 , followed by aqueous work-up and purification by plc gave (267c) (107mg, 87%).

Method C

- 5 The product of Method B (160 mg) obtained via the corresponding SO_2 adducts was similarly converted to the title compound.

Method D

The triethylsilyl ether of the title compound (160mg) obtained via the corresponding SO_2 adducts

- 10 in THF (10 ml) was stirred at room temperature with $n\text{-Bu}_4\text{NF}$ (1 N soln in THF, 2 ml). After about 30 min, the reaction was worked up as for (B) above, to give (267c) (101mg, 85%).

Crystalline from $\text{CH}_2\text{Cl}_2/\text{hexane}$: m.p. 104-106°C; $[\alpha]_D^{20} = +190^\circ$ (c = 0.37); UV λ_{max} 273nm (22640); ^1Hmr δ 6.5 and 5.83 (ABq, J = 11Hz, C-6H, 7H), 4.93 (s, C-19H), 4.62 (s, C-19H), 4.08-3.12 (m, C-3H, 22H₂), 1.05 (d, J = 5Hz, C-21H₃), 0.58 (s, C-18H₃); IR ν_{max} 3450 (s), 2980 (s), 2950 (sh), 1635 (w), 1450 (m), 1050 (s), 1030 (s), cm^{-1} ; mass spec. molecular ion $m/e = 330$; (analysis found: %C, 79.46; H, 9.94; $\text{C}_{22}\text{H}_{34}\text{O}_2$ requires %C, 79.95; H, 10.37).

Example 14

6(R),19-[N,N'-phthalhydrazido]-9,10-seco-3 β -acetoxy-20(S)-[p-toluenesulphonyloxymethyl]-pregna-5(10), 7(E)-diene

The alcohol from Example 3(1) (2.275g) in pyridine was stirred overnight with p-toluenesulphonylchloride (6.25g) at room temperature. Water was added to the ice cooled mixture and after about 20 min, the mixture extracted with CH_2Cl_2 . Acid work-up followed by crystallisation from $\text{CH}_2\text{Cl}_2/\text{ether}$ gave 2.5g (85%) of the required tosylate (216). m.p. 91-92°C; $[\alpha]_D^{20} = +308^\circ$ (c = 1.26); ^1Hmr δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl); and d, J = 7Hz, 2H, tosyl), 7.33 (d, J = 7Hz, 2H, tosyl), 5.85 (d, J = 10Hz, C-7H), 5.06 (m, C-3H), 4.70 and 4.2 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 3.8 (m, W = 12Hz, C-22H₂), 2.43 (s, tosyl), 2.03 (s, OAc), 0.88 (d, J = 5Hz, C-21H₃), 0.13 (s, C-18H₃); IR ν_{max} 2950 (s), 2900 (sh), 1750 (s), 1650 (s), 1610 (s), 1475 (s), 1240 (s), 1175 (s), cm^{-1} ; mass spec. molecular ion $m/e = 686$; (analysis found: %C, 68.09; H, 6.84; N, 4.00; S, 4.90; $\text{C}_{39}\text{H}_{46}\text{O}_7\text{N}_2\text{S}$ requires: %C, 68.19; H, 6.75; N, 4.08; S, 4.67).

Example 15

3-methyl-1-butyn-3-yl tetrahydropyranyl ether

3-Methyl-1-butyn-3-ol (25 ml, 21.7g), dihydropyran (50 ml) and p-toluenesulphonic acid (5mg) were mixed together at 0°C for 1 hr, and then stirred at room temperature for a further 40 hr. The mixture was concentrated and the residue added to 5% aqueous NaHCO_3 and extracted with benzene. The organic solution was dried to give after distillation 37.3g (86%) of the title ether. b.p. 47°C/0.8mm Hg (lit. 30-33°C/

0.5mm⁵⁰; 57°C/3.5mm¹⁷⁰; ¹Hmr δ 5.6 (m, THP C-2'H), 2.45 (s, C-1H), 1.51 (s, CH₃), 1.48 (s, CH₃); IR (thin film) 3350 (s), 2950 (s), 2900 (sh), 1125 (s), 1070 (s), 1030 (s), cm⁻¹.

Example 16

1-mercapto-2-methyl-2-hydroxy-propane

Ethyl-2-mercapto acetate (10 ml) was added to dry ether (150 ml). The well-stirred solution was cooled to 0°C, and an ethereal solution of methyl magnesium bromide (3 M soln, 100 ml, 3.3 eq) was added dropwise over 1.5 hr. The mixture was removed from the ice bath and stirred for an additional 30 min. Ammonium chloride (18g) in water was carefully added, and the mixture neutralised with hydrochloric acid to form 2 clear layers. The layers were separated and the ether layer washed with water/brine and dried. The solvent was removed under reduced pressure and the product distilled to give 4.4g of the thiol. b.p. 46°C/16mmHg (lit. 64°/26mmHg, 61°/22mmHg); ¹Hmr δ 2.6 (d, J = 9Hz, C-1H₂), 2.5 (s, exchanges with D₂O, -OH), 1.38 (t, J = 9Hz, -SH), 1.28 (s, 6H, -(CH₃)₂); mass spec. m/e 59 (100), 73(24), 91(14).

Example 17

6(R),19-[N,N'-phthalhydrazido]-23-thia-9,10-seco-3β-acetoxy-25-hydroxy-cholesta-5(10), 7(E)-diene

The acetylate from Example 14 (2.51g) in THF (125 ml) and HMPA (3 ml) was added 1-mercapto-2-methylpropan-2-ol from Example 16 (3 ml). The mixture was degassed.

1107

47283K

and NaH (50% dispersion in oil, 1.3g) was added. After 2 hr, water was added and the mixture diluted with benzene/CH₂Cl₂. Acid work-up followed by chromatography and crystallisation from CH₂Cl₂/ether gave 1.71g (77%) of the title sulphide. m.p. 187-188°C; [α]_D²⁰ = +348° (c = 0.62); ¹Hmr δ 8.3 (m, W = 12Hz, 2H, aryl), 7.8 (m, W = 10Hz, 2H, aryl), 5.9 (d, J = 10Hz, C-7H), 5.07 (m, C-3H), 4.78 and 4.18 (an AB system, J = 18Hz, C-19H₂), 4.75 (d, J = 10Hz, C-6H), 2.59 (s, C-24H₂), 2.03 (s, OAc), 1.23 (s, C-26H₃, 27H₃), 0.98 (d, J = 6Hz, C-21H₃), 0.15 (s, C-18H₃); IR v_{max} 3600 (m), 2950 (s), 2900 (sh), 1740 (s), 1640 (s), 1610 (m), 1370 (s), 1350 (s), 1240 (s), cm⁻¹; mass spec. molecular ion m/e = 620; (analysis found: % C, 69.47; H, 7.63; N, 4.43; S, 5.21; C₃₂H₄₈O₅N₂S requires: % C, 69.64; H, 7.79; N, 4.51; S, 5.17).

Example 18

23-thia-9,10-seco-3β,25-dihydroxy-cholesta-5(E), 7(E), 10(19)-triene

Prepared from the adduct of Example 17 as described in the general procedure as an oil. UV λ_{max} 273nm;

¹Hmr δ 6.52 and 5.83 (ABq, J = 11Hz, C-6H, 7H), 4.95 (s, C-19H), 4.67 (s, C-19H), 3.85 (m, W = 14Hz, C-3H), 2.63 (s, C-24H₂), 1.3 (s, C-26H₃, 27H₃), 1.1 (d, J = 6Hz, C-21H₃), 0.58 (s, C-18H₃).

Example 19

3-(3',5'-dinitrobenzoate)-ester

Prepared as described for the compound of Example 6(2) in 67% yield from the adduct of Example 17.

1108

47283K

0078704

Crystalline from ether/hexane. m.p. 108-110°C; $[\alpha]_D^{25} +188^\circ (c = 0.742)$; UV λ_{max} 272nm (25400) and 262nm (25400); $^1H_{NMR}$ δ 9.12 (m, 3H, aryl), 6.62 and 5.82 (ABq, $J = 11$ Hz, C-6H, 7H), 5.33 (m, 1H, C-3H), 5.08 (s, C-19H), 4.78 (s, C-19H), 2.63 (s, C-24H₂), 1.27 (s, C-26H₃), 27H₃, 1.08 (d, $J = 6$ Hz, C-21H₃), 0.45 (s, C-18H₃); IR ν_{max} 3600 (m), 2950 (s), 2900 (sh), 1740 (s), 1640 (m), 1550 (s), 1350 (s), 1280 (s), 1170 (s), cm^{-1} ; mass spec. molecular ion $m/e = 612$; (analysts found: % C, 64.39; H, 7.26; N, 4.43; S, 5.11; C₃₃H₄₄O₄N₂S requires: % C, 64.68; H, 7.24; N, 4.57; S, 5.23).

Example 20

23-thia-9,10-seco-la,38,25-bis(triethylsilyloxy)-cholesta-5(E), 7(E), 10(19)-triene

To the diol of Example 18 (400mg) in CH₂Cl₂ (15 ml) was added imidazole followed by triethylsilylchloride (450 μ l). After 7 hrs, water was added and the mixture diluted with CH₂Cl₂. Acid work-up gave the crude bis-TES derivative which was used without further purification.

Selenium dioxide (106mg) was stirred in methanol (5 ml) for 45 min. N-methylmorpholine-N-oxide (NMO) (528mg) was stirred in CH₂Cl₂ (5 ml) in the presence of anhydrous MgSO₄ for 30-min. The NMO solution was filtered into a solution of the crude bis-TES derivative in 1,2-dichloroethane (5 ml) and the mixture warmed to reflux. To this refluxing mixture was added the SeO₂/methanol. After 35 min at reflux, the heating mantle was removed, the mixture diluted with CH₂Cl₂ and washed immediately with 5% aqueous NaHCO₃ and dried. Purification by plc gave 233mg [35% from

1109

47283K

0078704

the adduct of Example 17 of the title 14-hydroxy compound as an oil. UV λ_{max} 274nm; $^1H_{NMR}$ δ 6.58 and 5.92 (ABq, $J = 12$ Hz, C-6H, 7H), 5.08 (s, C-19H), 4.97 (s, C-19H), 4.67-4.03 (m, C-1H, 3H), 2.58 (s, C-24H₂), 1.32 (s, C-26H₃, 27H₃).

Example 21

23-thia-9,10-seco-la,38,25-trihydroxy-cholesta-5(E), 7(E), 10(19)-triene

To the bis-TES derivative from Example 20 (112mg), in THF (5 ml), was added anhydrous tetrabutylammonium fluoride (220mg) in benzene (3 ml). After 2.25 hr at reflux, the mixture was diluted with ethylacetate, washed with water (3x)/brine and dried. The title triol (50mg, 68%) was isolated by plc. Crystalline from CH₂Cl₂/hexane. m.p. 129-131°C; $[\alpha]_D^{25} = +184^\circ (c = 0.2175)$; UV λ_{max} 273nm (21860); $^1H_{NMR}$ δ 6.58 and 5.92 (ABq, $J = 11$ Hz, C-6H, 7H), 5.12 (s, C-19H), 5.0 (s, C-19H), 4.65-4.0 (m, C-1H, 3H), 2.67 (s, C-24H₂), 1.28 (s, C-26H₃, 27H₃), 1.12 (d, $J = 7$ Hz, C-21H₃), 0.57 (s, C-18H₃); IR ν_{max} 3550 (s), 2950 (s), 2900 (sh), 1640 (w), 1050 (m), 1030 (m), cm^{-1} ; mass spec. molecular ion $m/e = 434$; (analysis found: % C, 71.57; H, 9.57; S, 7.23; C₂₆H₄₂O₃ requires: % C, 71.84; H, 9.74; S, 7.38).

Example 22

23-thia-9,10-seco-38,25-dihydroxy-cholesta-5(Z), 7(E), 10(19)-triene

A solution of the 5,6-trans-trans vitamin from Example 20 (64mg) in benzene (30 ml) containing triethylamine (1 drop) and antracene (15mg) was

1110

47283K

0078704

thoroughly degassed and photoisomerised as described in Example 6(1). The mixture was irradiated for 20 min and the required title vitamin (49mg, 77%)

isolated by plc as an oil. UV λ_{max} 262nm; $^1\text{Hnmr}$ δ 6.25 and 6.0 (ABq, J = 11Hz, C-6H, 7H), 5.03 (s, C-19H), 4.82 (s, C-19H), 3.93 (m, W = 18Hz, C-3H), 2.67 (s, C-24H₂), 1.27 (s, C-26H₃, 27H₃), 1.08 (d, J = 6Hz, C-21H₂), 0.55 (s, C-18H₃).

Example 23

The 3-(3',5'-dinitrobenzoate ester of the product of Example 22 was prepared using the method of Example 6(2).

Crystalline from ether/hexane. m.p. 145-148°C; $[\alpha]_D^{25} = +109^\circ$ (c = 0.571); UV λ_{max} shoulders at 260nm (24900) and

235nm (30600); $^1\text{Hnmr}$ δ 9.08 (m, 3H, aryl), 6.33 and 6.06 (ABq, J = 11Hz, C-6H, 7H), 5.33 (m, C-3H), 5.15 (s, C-19H), 4.93 (s, C-19H), 2.65 (s, C-24H₂), 1.27 (s, C-26H₃, 27H₃), 1.08 (d, J = 6Hz, C-21H₂), 0.57 (s, C-18H₃). IR ν_{max} 3750 (m), 2950 (s), 2900 (sh), 1750 (s), 1640 (s), 1550 (s), 1345 (s), 1280 (s), 1170 (s), cm^{-1} ; mass spec. molecular ion m/e = 612; (analysis found: % C, 64.7; H, 7.24; O, 18.25; N, 4.36; S, 5.15; $\text{C}_{33}\text{H}_{44}\text{O}_7\text{N}_2\text{S}$ requires: % C, 64.68; H, 7.24; O, 18.28; N, 4.57; S, 5.23).

Example 24

23-thia-9,10-seco-la-38,25-bis(triethylsiloxy)-cholesta-5(Z),7(E),10(19)-triene

The corresponding 5(E) compound of Example 20 (180mg) in benzene (35 ml) containing phenazine (40mg) and triethylamine (4 drops) was thoroughly

47283K

1111

0078704

degassed and irradiated as described above for 35 min. 137mg (75%) of the less polar 5(Z) compound was isolated as an oil by plc. UV λ_{max} 263nm; $^1\text{Hnmr}$ δ 6.35 and 6.05 (ABq, J = 11Hz, C-6H, 7H), 5.27 (s, C-19H), 4.95 (s, C-19H), 4.6-3.93 (m, C-1H, 3H), 2.57 (s, C-24H₂), 1.2 (s, C-26H₃, 27H₃).

Example 25

23-thia-9,10-seco-la-38,25-trihydroxy-cholesta-5(Z),7(E),10(19)-triene

To the corresponding bis TES derivative from Example 24 (185mg) in THF (8 ml) was added tetrabutylammonium

fluoride (1 M soln in THF, 2ml). After 1.25 hr at reflux,

the mixture was diluted with CH_2Cl_2 . Aqueous work-up

and purification by plc gave 110 mg (90%) of the title triol. Crystalline from ether/hexane. m.p. 124-126°C; $[\alpha]_D^{25} = +54^\circ$ (c = 0.37); UV λ_{max}

264nm (17400); $^1\text{Hnmr}$ δ 6.35 and 6.05 (ABq, J = 11Hz, C-6H, 7H), 5.33 (s, C-19H), 5.0 (s, C-19H), 4.65-4.0 (m, C-1H, 3H), 2.63 (s, C-24H₂), 1.27 (s, C-26H₃, 27H₃), 1.1 (d, J = 6Hz, C-21H₂), 0.55 (s, C-18H₃); IR ν_{max} 3550 (s), 2950 (s), 2900 (sh), 1640 (w), 1050 (m), 1030 (m), cm^{-1} ; mass spec. molecular ion m/e = 434; (analysis found: % C, 71.63; H, 9.61; S, 7.34; $\text{C}_{26}\text{H}_{42}\text{O}_3\text{S}$ requires: % C, 71.84; H, 9.74; S, 7.38).

Example 26

23-thia-9,10-seco-la-38-bis(3',5'-dinitrobenzoyloxy)-25-hydroxy-cholesta-5(Z),7(E),10(19)-triene

To the triol from Example 25 (75mg) in pyridine (3 ml) and benzene (5 ml) was added 3,5-dinitrobenzoylchloride

1112

47283K

0078704

(85mg). Water was added and the mixture diluted with ether. Work-up as in Example 6(2) and purification by plc gave 97mg (68%) of the unstable bis (dinitrobenzoate). ^1Hmr δ 9.8 (m, 6H, aryl), 6.62 (d, $J = 11\text{Hz}$, C-6H), 6.12-5.42 (m, C-1H, 3H, 7H, 19H), 5.32 (s, C-19H), 2.63 (s, C-24H₂), 1.27 (s, C-26H₃, 27H₃), 1.08 (broad singlet, C-21H₃), 0.22 (s, C-18H₃).

Example 27

652138/39

23-thia-9,10-seco-1 α ,3 β -25-trihydroxy-cholesta-5(Z),7(E),10(19)-triene-23,5-oxides

The sulphide from Example 25 (100mg) in methanol (110 ml), ether and water (2 ml) was stirred at room temperature with sodium metaperiodate (50mg). After 3 hr, a further addition of oxidant (20mg) was made.

After a total of 5 hr, the mixture was diluted with CH₂Cl₂. Aqueous work-up followed by plc gave 92mg (89%) of the title sulphoxide mixture. Solid from acetone, methanol/hexane, ether. m.p. 148-155°C; $[\alpha]_D^{25} = +77^\circ$ ($c = 0.691$); UV λ_{max} 263nm (18150); ^1Hmr δ 6.35 and 6.05 (ABq, $J = 11\text{Hz}$, C-6H, 7H), 5.33 (s, C-19H), 5.0 (s, C-19H), 4.62-3.72 (m, C-1H, 3H, -OH, exchanges with D₂O), 2.83 and 2.75 (broad singlets, C-24H₂), 1.52 and 1.38 (C-26H₃, 27H₃), 1.23 (broad singlet, C-21H₃), 0.6 (s, C-18H₃); IR ν_{max} 3500 (s), 3300 (s), 2950 (s), 2900 (sh), 1620 (w), 1380 (s), 1220 (s), 1070 (s), 1050 (s), 1030 (s), 1000 (s). $m/e = 450$; mass spec. molecular ion $m/e = 450$; (analysis found: % C, 69.05; H, 9.44; S, 7.13; C₂₆H₄₂O₄S requires: % C, 69.29; H, 9.39; S, 7.12).

1113

47283K

0078704

Example 28

23-oxa-9,10-seco-3 β ,25-dihydroxy-cholesta-5(E),7(E),10(19)-triene

The silyl ether from Example 52 (160mg) was stirred with n-Bu₄NF (1 M soln in THF, 1 ml) in refluxing THF (5 ml) for 40 min. Dilution with CH₂Cl₂, followed by aqueous work-up and purification by plc gave the title compound (102mg, 82%). UV λ_{max} 274nm; ^1Hmr δ 6.47 and 5.85 (ABq, $J = 11\text{Hz}$, C-6H, 7H), 4.9 (s, C-19H), 4.63 (s, C-19H), 3.83 (m, $W = 18\text{Hz}$, C-3H), 3.58-3.07 (m, C-22H₂), 3.18 (s, C-24H₂), 1.2 (s, C-26H₃, 27H₃), 1.03 (d, $J = 6\text{Hz}$, C-21H₃), 0.58 (s, C-18H₃).

Example 29

The 3-(3'-5'-dinitrobenzoate) ester of the product of Example 28 was prepared as described previously for Ex. 6(2). Crystalline from ether/hexane. m.p. 75-77°C; $[\alpha]_D^{25} = +176^\circ$ ($c = 0.58$); ^1Hmr δ 9.15 (m, 3H, aryl), 6.58 and 5.78 (ABq, $J = 11\text{Hz}$, C-6H, 7H), 5.3 (m, $W = 12\text{Hz}$, C-3H), 5.03 (s, C-19H), 4.73 (s, C-19H), 3.57-3.07 (m, C-22H₂), 3.2 (s, C-24H₂), 1.22 (s, C-26H₃, 27H₃), 1.02 (d, $J = 6\text{Hz}$, C-21H₃), 0.47 (s, C-18H₃); IR ν_{max} 3500 (m), 2950 (s), 2900 (sh), 1730 (s), 1640 (m), 1550 (s), 1460 (m), 1340 (s), 1270 (s), 1165 (m), cm^{-1} ; mass spec. molecular ion $m/e = 596$; (analysis found: % C, 66.31; H, 7.55; N, 4.56; C₃₃H₄₄O₈N₂ requires: % C, 66.42; H, 7.43; N, 4.70).

1114

47283K

0078704

Example 30

23-oxa-9,10-seco-3 β -(t-butyldimethylsilyloxy)-25-hydroxy-cholesta-5(Z),7(E),10(19)-triene

The corresponding 5(E) compound from Example 52 (160mg) in benzene (30 ml) and triethylamine (3 drops) containing phenazine (35mg) was thoroughly degassed and irradiated as described above for 30 min. Purification by plc gave (273a) (138mg, 86%). UV max = 263nm; $^1\text{Hnmr}$ δ 6.25 and 6.0 (ADq, J = 11Hz, C-6H, 7H), 5.05 (s, C-19H), 4.82 (s, C-19H), 3.92 (m, W = 18Hz, C-3H), 3.62-3.10 (m, C-22H₂), 3.20 (s, C-24H₂), 1.23 (s, C-26H₃, 27H₃), 1.03 (d, J = 6Hz, C-21H₃), 0.91 (s, t-Bu), 0.58 (s, C-18H₃), 0.05 [s, (Si-CH₃)₂].

Examp. plc 31

23-oxa-9,10-seco-3 β ,25-dihydroxy-cholesta-5(Z),7(E),10(19)-triene

The corresponding 3-t-butyldimethylsilyl ether from Example 30 (138mg) was stirred with n-Bu₄NF (1 M soln) in THF, 2 ml) in refluxing THF (5 ml). After 45 min, the mixture was diluted with CH₂Cl₂. Aqueous work-up followed by purification by plc gave the diol (273b) (91mg, 85%) as an oil. UV λ_{max} 263nm; $^1\text{Hnmr}$ δ 6.24 and 6.04 (ABq, J = 11Hz, C-6H, 7H), 5.03 (s, C-19H), 4.83 (s, C-19H), 3.92 (m, W = 18Hz, C-3H), 3.57-3.12 (m, C-22H₂), 3.25 (s, C-24H₂), 1.22 (s, C-26H₃, 27H₃), 1.03 (d, J = 6Hz, C-21H₃), 0.57 (s, C-18H₃).

1115

47283K

0078704

Example 32

The 3-(3',5'-dinitrobenzoate) ester of the product of Example 31 was prepared as in Example 6(2). Crystalline from ether/hexane m.p. 136-138°C; $[\alpha]_D^{20} = +101^\circ$ (c = 0.615); $^1\text{Hnmr}$ δ 9.12 (m, 3H, aryl), 6.22 and 6.01 (ABq, J = 11Hz, C-6H, 7H), 5.23 (m, W = 18Hz, C-3H), 5.1 (s, C-19H), 4.92 (s, C-19H), 3.57-3.1 (m, C-22H₂), 3.2 (s, C-24H₂), 1.22 (s, C-26H₃, 27H₃), 1.05 (d, J = 6Hz, C-21H₃), 0.53 (s, C-18H₃); IR ν_{max} 3550 (m), 2950 (s), 2900 (sh), 1750 (s), 1650 (m), 1555 (s), 1470 (m), 1350 (s), 1280 (s), cm⁻¹; mass spec. molecular ion m/e = 596; (analysis found: % C, 66.34; H, 7.37; N, 4.61; C₃₃H₄₄O₈N₂ requires: % C, 66.42; H, 7.43; N, 4.70).

Example 33

23-oxa-9,10-seco-3 β -(t-butyldimethylsilyloxy)-25-(triethylsilyloxy)-cholesta-5(E),7(E),10(19)-triene

The 25-hydroxy compound from Example 52 (300mg) in CH₂Cl₂ (10 ml) was treated with triethylsilylchloride (130 μ l) in the presence of imidazole (200mg) for 16 hrs. Acid work-up gave the title bis silylated calciferol (274) which was used in the next step without further purification.

Example 34

23-oxa-9,10-seco-1 α -hydroxy-3 β -(t-butyldimethylsilyloxy)-25-(triethylsilyloxy)-cholesta-5(E),7(E),10(19)-triene

Selenium dioxide (60mg) was stirred in methanol (4 ml) for 45 mins. NMO (300mg) was stirred in CH₂Cl₂ (4 ml) in the presence of anhydrous MgSO₄ for 30 min. The NMO solution was filtered into a solution of the

1116

47283K

0078704

- 54 -

bis silyl ether from Example 33 in 1,2-dichloroethane (4 ml) and the mixture warmed to reflux. To this refluxing mixture was added the SeO_2 /methanol mixture. After 23 min, the heating mantle was removed and the product worked up and isolated as described previously to give 190 mg (51% based on ~~652~~) of the title 14-hydroxylated product. UV λ max 274nm; $^1\text{Hnmr}$ δ 6.55 and 5.88 (ABq, J = 12Hz, C-6H, 7H), 5.1 (s, C-19H), 5.0 (s, C-19H), 4.75-4.02 (m, C-1H, 3H), 3.65-3.12 (m, C-22H₂), 3.25 (s, C-24H₂).

Example 35

23-oxa-9,10-seco-la,3a,25-trihydroxy-cholesta-5(E),7(E),10(19)-

triene

The bis silyl ether from Example 34 (190mg) in THF (6 ml) was refluxed with nBu_4NF (1 M solution in THF, 2 ml) for 1 hr. The mixture was diluted with CH_2Cl_2 . Aqueous work-up gave the title triol (103 mg).

84%) after purification by plc. Crystalline from chloroform/hexane. mp 141-144°C, $[\alpha]_D^{25} = +144^\circ$ ($c = 0.355$); UV λ max 272nm (20554); $^1\text{Hnmr}$ (400MHz) δ 6.58 (d, J = 12Hz) 5.89 (d, J = 12Hz) 5.13 (s, C-19H), 4.98 (s, C-19H), 4.50 (m, W = 12Hz, C-1H), 4.26 (m, W = 20Hz, C-3H), 3.43 (m, 1H), 3.30-3.15 (m, C-22H₂, 24H₂), 1.20 (s, C-26H₃, 27H₃), 1.02 (d, J = 6Hz, C-21H₃), 0.58 (s, C-18H₃); IR ν_{max} 3500 (s), 2950 (s), 2900 (sh), 1640 (w), 1450 (m), 1380 (m), 1360 (m), 1045 (s), cm^{-1} ; mass spec. molecular ion m/e

- 1117

47283K

0078704

- 55 -

= 418; (analysis found: % C, 74.76; H, 10.33; $\text{C}_{26}\text{H}_{40}\text{O}_4$ requires: % C, 74.60; H, 10.11).

Example 36

23-oxa-9,10-seco-la-hydroxy-3a-(t-butylidimethylsilyloxy)-25-(triethylsilyloxy)-cholesta-5(Z),7(E),10(19)-triene

The corresponding 5(E) compound from Example 35 (200mg) in benzene (35 ml) containing phenazine (40mg) and triethylamine (4 drops) was irradiated with the hanovia lamp as described previously for 35 min to give, after purification by plc, 155mg (78%) of the title compound as a less polar, oily product. UV λ max 263nm; $^1\text{Hnmr}$ δ 6.30 and 6.01 (ABq, J = 12Hz, C-6H, 7H), 5.23 (s, C-19H), 4.97 (s, C-19H), 4.67-3.9 (m, C-1H, 3H), 3.53-3.07 (m, C-22H₂), 3.17 (s, C-24H₂).

Example 37

23-oxa-9,10-seco-la,3a,25-trihydroxy-cholesta-5(Z),7(E),10(19)-triene

The bis silyl ether from Example 36 (155mg) and $\text{n-Bu}_4\text{NF}$ (1 M soln in THF, 2 ml) were stirred together in refluxing THF (5 ml) for 1 hr. Dilution with CH_2Cl_2 followed by aqueous work-up and purification by plc gave the title triol (252a) (77mg, 77%). Crystalline from ether/hexane. m.p. 121-123°C; $[\alpha]_D^{25} = +47^\circ$ ($c = 0.6$); UV λ max 264nm (17200); $^1\text{Hnmr}$ δ 6.37 and 6.05 (ABq, J = 11Hz, C-6H, 7H), 5.33 (s, C-19H), 5.0 (s, C-19H),

1118

47283K

0078704

4.57-3.87 (m, C-1H, 3H), 3.6-3.1 (m, C-2H₂), 3.23 (s, C-2H₂), 1.23 (s, C-26H₃, 27H₃), 1.05 (d, J = 6Hz, C-21H₃), 0.58 (s, C-18H₃); IR ν_{\max} 3500 (s), 2950 (s), 2900 (sh), 1640 (w), 1450 (m), 1380 (m), 1360 (m), 1045 (s), cm^{-1} ; mass spec. molecular ion m/e = 418; [analysis found: % C, 74.47; H, 9.97; C₂₆H₄₂O₄ requires: % C, 74.60; H, 10.11].

Example 38

9,10-seco-38-(triethylsilyloxy)-20(S)-(p-toluenesulphonyloxymethyl)-pregna-5(E), 7(E), 10(19)-triene.

Method A

To the hydroxy compound from Example 13(D) (400mg) in pyridine (5 ml) was added tosylchloride (350mg) and the mixture stirred overnight at room temperature. Water was added and the mixture diluted with ether. Acid work-up gave, after purification by plc, 310mg (58%) of the title tosylate

$^1\text{Hnmr}$ δ 7.73 (d, J = 8Hz, 2H, aryl), 7.28 (d, J = 8Hz, 2H, aryl), 6.43 and 5.81 (ABq, J = 11Hz, C-6H, 7H), 4.92 (s, C-19H), 4.63 (s, C-19H), 4.2-3.57 (m, C-3H, 22H₂), 2.48 (s, aryl-CH₃); IR ν_{\max} (thin film) 2960 (s), 2900 (sh), 1600 (w), 1460 (m), 1360 (s), 1190 (s), 1175 (s), 1090 (s), cm^{-1} .

Method B

The crude SO₂ adducts of 9,10-seco-38-triethylsilyloxy-20(S)-(hydroxymethyl)-pregna-5(E), 7(E), 10(19)-triene from Example 12(1) (3.2g) was stirred overnight in pyridine (40 ml) at 5°C with p-toluenesulphonyl chloride (4g).

1119

47283K

0078704

The reaction was cooled to 0°C, water added and, after a few minutes, the mixture was diluted with Et₂O. After an acid work-up, the crude oily product (281) was taken up in ethanol (100 ml) and refluxed in the presence of NaHCO₃ (4g) for 1 hr. The mixture was concentrated and partitioned between CH₂Cl₂/water/brine. The organic solution was dried and chromatographed to give 2.64g (70%) of the required vitamin (278c) nmr and IR identical to the product obtained by Method A.

Example 39

9,10-seco-38-(hydroxy-20(S)-(fluoromethyl)-pregna-5(E), 7(E), 10(19)-triene

The tosylate from Example 38 (200mg) in THF (5 ml) was refluxed for 45 min in the presence of n-Bu₄NF (1 M soln in THF, 1 ml). The mixture was diluted with CH₂Cl₂. Aqueous work-up followed by purification by plc gave 70mg (63%) of the title fluoride (279). $^1\text{Hnmr}$ δ 6.5 and 5.83 (ABq, J = 11Hz, C-6H, 7H), 4.97 (s, C-19H), 4.7 (br, s, C-19H, 22H), 4.2-3.6 (m, C-3H, 22H), 1.1 (d, J = 6Hz, C-21H₃), 0.6 (s, C-18H₃).

Example 40

9,10-seco-1a-hydroxy-38-(triethylsilyloxy)-20(S)-(p-toluenesulphonyloxymethyl)-pregna-5(E), 7(E), 10(19)-triene

Selenium dioxide (56mg) was stirred in acetonitrile (3.5 ml) for 45 min. MMO (280mg) was stirred in CH₂Cl₂ (3.5 ml) in the presence of anhydrous MgSO₄ for 30 min. The MMO solution was filtered into a solution of the 1-desoxy compound from Example 38 (300mg) in 1,2-dichloroethane (3.5 ml) and the mixture warmed to reflux. To this was added the SeO₂/CH₃CN mixture, and refluxing continued for a further 5.5 min. The reaction mixture was cooled in an ice bath, diluted with CH₂Cl₂ and

1120

47283K

0078704

worked up as described previously to give 180mg. (57%) of the title 1-hydroxy compound.

$^1\text{Hnmr}$ δ 7.73 (d, J = 8Hz, 2H, aryl), 7.28 (d, J = 8Hz, 2H, aryl), 6.43 and 5.81 (ABq, J = 11Hz, C-6H, 7H), 5.03 (s, C-19H), 4.93 (s, C-19H), 4.63-3.6 (m, C-1H, 3H, 22H₂), 2.48 (s, aryl-CH₃).

Example 41

9,10-seco-1a,3a-dihydroxy-20(S)-(p-toluenesulphonyloxymethyl)-pregna-5(E),7(E),10(19)-triene

The 3-triethylsilyl ether derivative from Example 40

(180mg) in THF (5 ml) containing n-Bu₄NF (1 M soln in THF, 0.4 ml) was stirred for 15 min. The mixture was diluted with CH₂Cl₂. An aqueous work-up and purification by plc gave 118mg (81%) of the title diol. Solid from CH₂Cl₂/hexane. m.p. 97-99°C; $[\alpha]_D^{20} = +132^\circ$ (c = 0.57); UV λ_{max} 272nm (23360) and 210nm (15920); $^1\text{Hnmr}$ δ 7.73 (d, J = 8Hz, 2H, aryl), 7.28 (d, J = 8Hz, 2H, aryl), 6.43 and 5.81 (ABq, J = 11Hz, C-6H, 7H), 5.03 (s, C-19H), 4.93 (s, C-19H), 4.63-3.53 (m, C-1H, 3H, 22H₂), 2.5 (s, aryl-CH₃), 1.02 (d, J = 6Hz, C-21H₃), 0.57 (s, C-18H₃); IR ν_{max} 3500 (s), 2950 (s), 2900 (sh), 1600 (w), 1450 (m), 1355 (s), 1190 (s), 1175 (s), cm⁻¹.

Example 42

9,10-seco-1a-hydroxy-3a-(triethylsiloxy)-20(S)-(p-toluenesulphonyloxymethyl)-pregna-5(Z),7(E),10(19)-triene

The corresponding 5(F) compound from Example 40

(225mg) in benzene (35 ml) containing triethylamine (3 drops) was irradiated as described above with anthracene (45mg) as triplet sensitizer for 30 min to give,

1121

47233K

0078704

after plc. 185mg (82%) of the title compound. UV λ_{max} 263nm and 216nm;

$^1\text{Hnmr}$ δ 7.73 (d, J = 8Hz, 2H, aryl), 7.3 (d, J = 8Hz, 2H, aryl), 6.28 and 5.98 (ABq, J = 11Hz, C-6H, 7H), 5.28 (s, C-19H), 4.92 (s, C-19H), 4.55-3.58 (m, C-1H, 3H, 22H₂), 2.45 (s, aryl-CH₃).

Example 43

9,10-seco-1a,3a-dihydroxy-20(S)-(p-toluenesulphonyloxymethyl)-pregna-5(Z),7(E),10(19)-triene

The silyl ether from Example 43 (135mg) in THF (5 ml) containing n-Bu₄NF (1 M soln in THF, 0.32 ml) was stirred for 15 min at room temperature. Dilution with CH₂Cl₂ aqueous work-up and purification by plc gave the title diol (110mg, 73%). UV λ_{max} 263nm (17427) and 216nm (18672); $^1\text{Hnmr}$ δ 7.68 (d, J = 8Hz, 2H, aryl), 7.23 (d, J = 8Hz, 2H, aryl), 6.28 and 5.97 (ABq, J = 11Hz, C-6H, 7H), 5.27 (s, C-19H), 4.93 (s, C-19H), 4.57-3.6 (m, C-1H, 3H, 22H₂), 2.45 (s, aryl-CH₃), 1.05 (d, J = 6Hz, C-21H₃), 0.52 (s, C-18H₃).

Example 44

1-amino-2-methyl-2-hydroxy-propane

To a well-stirred mixture of lithium aluminium hydride (12g) in ether (200 ml) at 0°C was added dropwise over 1 hr a solution of acetone cyanohydrin (11.2g, 12 ml) in ether (50 ml). The mixture was stirred at room temperature overnight. After cooling to 0°C, water (24 ml) was cautiously added dropwise. After the quenching was complete, anhydrous Na₂SO₄ (65g) was added and stirring at room temperature was continued for a further 2.5 hr. The solid was filtered off and the ether evaporated to give, after distillation, 4.8g (41%) of

1122

47233K

the title compound as a viscous, colourless liquid.

b.p. 74-76°C/14mm Hg (lit. 169-62-64°C/13mm Hg) $n_D^{20} = 1.4463$
(lit. 169 $n_D^{20} = 1.4467$); $^1\text{Hnmr}$ δ 2.6 (s, 2H), 1.87 (s, 3H, exchanges
with D_2O), 1.2 (s, 6H); IR ν_{max} (thin film) 3400 (s), 3000 (m), 1600
(m), 1475 (m), 1380 (m), 1360 (m), 1220 (m), 1170 (m), 1110 (m), 960
(m), cm^{-1} .

Example 45

23-aza-9,10-seco-la,3 β ,25-trihydroxy-cholesta-5(Z),7(E),10(19)-triene

A solution of the tosylate from Example 44 (100mg)

in 1-amino-2-methyl-2-hydroxy-propane (0.5 ml) was degassed
and then stirred under argon at 50-55°C for 6 hr and then
at room temperature for a further 12 hr. The solution was
diluted with CH_2Cl_2 and washed with water/brine and dried to

give, after purification by plc, 44 mg (53%) of the title triol.

$[\alpha]_D^{20} = +24^\circ$; UV λ_{max} 264nm (15400); $^1\text{Hnmr}$ δ 6.38 and 6.07 (ABq, J =
11Hz, C-6H, 7H); 5.35 (s, C-19H), 5.02 (s, C-19H), 4.67-3.93 (m, C-1H,
3H), 2.5 (s, C-24H₂), 1.2 (s, C-26H₃, 27H₃), 1.02 (d, J = 6Hz, C-21H₃),
0.57 (s, C-18H₃); IR ν_{max} 3500 (s), 2950 (s), 2900 (sh), 1640 (w),
1460 (m), 1380 (m), 1055 (m), cm^{-1} ; mass measurement found: 417.3242;
 $\text{C}_{26}\text{H}_{43}\text{O}_3\text{N}$ requires: 417.3243.

Example 46

23-aza-9,10-seco-la,3 β ,25-trihydroxy-cholesta-5(Z),7(E),10(19)-triene-23-N-acetyl

1123

47283K

The crude amine from Example 45 derived from the
tosylate (100mg) as described above, in methanol (5 ml)
containing K_2CO_3 (500mg) was treated with acetic anhydride
(0.2 ml). The mixture was diluted with CH_2Cl_2 washed with
brine and dried to give, after plc, 50mg (55% from tosylate)
of the title amide. Solid from CH_2Cl_2 /hexane. m.p. 107-109°C;

$[\alpha]_D^{20} = -14^\circ$ (c = 0.49); UV λ_{max} 263nm (16275); $^1\text{Hnmr}$ δ 6.37 and 6.05
(ABq, J = 11Hz, C-6H, 7H), 5.33 (s, C-19H), 5.0 (s, C-19H), 4.65-4.02
(m, C-1H, 3H), 3.4 (s, C-24H₂), 2.17 (s, acetyl), 1.22 (s, C-26H₃, 27H₃),
0.95 (d, J = 7Hz, C-21H₃), 0.6 (s, C-18H₃); IR ν_{max} 3550 (s), 2950 (s),
2900 (sh), 1640 (s), 1460 (m), 1380 (m), 1055 (m), cm^{-1} ; (analysis found:
% C, 70.80; H, 10.12; N, 2.77; $\text{C}_{28}\text{H}_{45}\text{O}_4\text{N}$ requires: C, 73.16; H, 9.87;
N, 3.05; $\text{C}_{28}\text{H}_{45}\text{O}_4\text{N} \cdot \text{H}_2\text{O}$ requires: % C, 70.40; H, 9.92; N, 2.93).

Example 47

9,10-seco-3 β ,25-dihydroxy-cholesta-5(E),7(E),10(19)-triene

Magnesium turnings were washed with diluted HCl/water/acetone/ether
and dried in vacuo for 24 hr. The 1-bromo-4-methyl-4-
triethylsilylbutane (1g) in freshly distilled (from LiAlH_4)
THF (10 ml) containing magnesium metal (82mg) was refluxed
for 2 hr.

Cuprous iodide (100 mg) was placed in a flask and purged with
argon, whilst cooling to 0°C. To this was added the above Grignard
solution (5 ml), and the purple coloured mixture stirred for an addi-
tional 30 min at 0°C. A solution of the tosylate (278e) (200mg) in
ether (2 ml) was added and the mixture stirred for 40 min at room
temperature. Water was added and the reaction mixture extracted with

1124

47283K

0078704

ether. After an acid work-up, the non-polar product was isolated by plc contaminated with large quantities of low molecular weight alkyl residues. This mixture was stirred with $n\text{-Bu}_4\text{NF}$ (1 M soln in THF, 2 ml) in refluxing THF (5 ml) for 2 hr. Dilution with CH_2Cl_2 followed by aqueous work-up and purification by plc gave 110mg [82% from tosylate (276c)] of this previously described title diol. The physical and spectral properties of this material were identical in all respects to the product obtained from the phthalazine adduct.

Example 40

9,10-seco-3 β ,25-dihydroxy-cholest-5(Z),7(E),10(19)-triene

The product from Example 47 (100mc) in benzene (30 ml) and triethylamine (3 drops) containing anthracene (25mg) was thoroughly degassed and irradiated for 1 hr as described above to give, after purification by plc, the title 5(Z) compound (90mg, 82%). The physical and spectral properties of this material were identical in all respects to the product obtained via the phthalazine adduct. A mixed melting point determination of this material and an authentic sample, kindly supplied by Roussel Uclaf, Inc (Romainville, France) was undepressed.

Example 49

9,10-seco-1 α ,3 β -bis(triethylsilyloxy)-20(S)-(p-toluenesulphonyloxymethyl)-pregna-5(Z),7(E),10(19)-triene

The tosylate (276b) (105mg) in CH_2Cl_2 (5 ml) containing imidazole (75mg) and triethylsilylchloride (45 μ l) was stirred at room temperature for about 15 min. Water was added and the mixture diluted with

1125

47203K

0078704

CH_2Cl_2 . Acid work-up gave the non-polar title bis silyl ether which was used without further purification.

Example 50

9,10-seco-1 α ,3 β ,25-trihydroxy-cholesta-5(Z),7(E),10(19)-triene

To the alkyl copper reagent at 0°C prepared exactly as described above, was added a solution of the above tosylate (276c) in THF (3 ml) and the mixture stirred at room temperature for 25 min. Work-up and purification as in Example 6(1) gave the tris triethylsilyl derivative contaminated with large quantities of low molecular weight alkyl residues. This mixture was treated with $n\text{-Bu}_4\text{NF}$ (1 M soln in THF, 4 ml) in THF (5 ml) for 20 min at room temperature followed by 1.5 hr at reflux to give, after the usual work-up and purification by plc, a mixture of the title steroidal triol [(38mg, 63% from (276b)] contaminated with the iso-pentane diol (10mg). Dissolution of this mixture in CHCl_3 gave the required product as its crystalline CHCl_3 solvate (25mg). m.p. 99-105°C (lit. 106-112°C¹⁴², 103-106°C¹³⁰); $[\alpha]_D^{20} = +35^\circ$ (c = 0.86); UV λ_{max} 264nm (16820); $^1\text{Hnmr}$ δ (acetone- d_6) 8.07 (s, CHCl_3), 6.35 and 6.18 (ABq, J = 12Hz, C-6H, 7H), 5.38 (s, C-19H), 4.93 (s, C-19H), 4.7-4.07 (m, C-1H, 3H), 1.2 (s, C-26H₃, 27H₃), 1.0 (broad singlet, C-21H₃), 0.6 (s, C-18H₃); IR ν_{max} 3500 (s), 2950 (s), 2900 (sh), 1640 (w), 1480 (m), 1440 (m), 1380 (m), 1360 (m), 1140 (m), 1050 (s).

1126

47203K

Claims

1. Compounds of the general formula


Example 51

23-oxa-9,10-seco-3 β -(t-butyl(dimethylsilyloxy)-25-hydroxy-cholesta-5(E), 7(E), 10(19)-triene

The 22-hydroxy compound (167b) (425mg) in benzene (5 ml) was refluxed with isobutylene epoxide (1 ml) in the presence of dibenzo-18-crown-6 (100 mg) and potassium t-butoxide (500 mg) for 55 min. Water was added and the mixture diluted with CH_2Cl_2 . The organic layer was washed with aqueous K_3PO_4 /water/5% aqueous NaHCO_3 /brine and dried. Purification by plc gave 330mg (67%) of the slightly less polar oily product. $^1\text{Hnmr } \delta$ 6.45 and 5.85 (ABq, J = 12Hz, C-6H, 7H), 4.9 (s, C-19H), 4.63 (s, C-19H), 3.92 (m, W = 18Hz, C-3H), 3.63-3.12 (m, C-22H₂), 3.22 (s, C-24H₂), 1.23 (s, C-26H₃, 27H₃), 1.05 (d, J = 6Hz, C-21H₃), 0.92 (s, t-Bu), 0.6 (s, C-18H₃), 0.05 s, [(Si-CH₃)₂].

1127

47283K




- wherein R represents a hydrogen atom or a hydroxyl
5 protecting group, Y represents a hydrogen atom or an optionally protected hydroxyl group, X represents the residue of a dienophile and either R¹ represents a halogen atom a hydrocarbylsulphonyloxy group or a group of the formula -Z-R³ (in which Z represents 10 -O-, -S-, -SO-, -NR⁴- or -CR⁵- and R³, R⁴ and R⁵, which may be the same or different, each represent a hydrogen atom or a straight or branched aliphatic group having 1-12 carbon atoms and which may optionally carry one or more substituents) and R² represents 15 a hydrogen atom or R¹ and R² together represent an oxo group or an optionally substituted alkylidene group, except that R¹ and R² together with the group -CH(CH₃)CH- to which they are attached do not represent a group having the branched 17 β -hydrocarbyl side chain skeleton of vitamin D₂ or vitamin D₃.
- 20 2. Compounds as claimed in claim 1 in which the dienophile is SO₂ or a diacylazo compound.

1128

47283K

3. Compounds of general formula IV or IVa,



wherein R, Y, R¹ and R² are as defined in claim 1.
 4. Compounds of general formulae I, IV or IVa as claimed in any one of claims 1 to 3 wherein R¹ represents a halogen atom, a hydroxyl or tosyloxy group or a group of formula:




(in which Z' represents -O-, -S-, -NH- or -SO- and R⁶ represents a hydrogen atom or a hydroxyl protecting group) and R² represents a hydrogen atom or R¹ and R² together represent an alkylidene group having 1 to 8 carbon atoms optionally substituted by one or more substituents selected from halogen atoms and optionally protected hydroxyl groups.
 5. A process for the preparation of compounds of general formula I as defined in claim 1 in which R¹ and R² together represent an oxo group which comprises

1129

47283K

subjecting a compound of formula III,



(wherein R, Y and X are as defined in claim 1) to oxidative cleavage.
 6. A process as claimed in claim 5 wherein the aldehyde of formula I so formed is subsequently reduced to give a compound of formula I wherein R¹ represents a hydroxyl group.
 7. A process as claimed in claim 5 wherein the aldehyde of formula I so formed is subsequently reacted with a Wittig reagent to give a compound of formula I wherein R¹ and R² together represent an optionally substituted alkylidene group, the double bond of which may then, if desired, be reduced.
 8. A process for the preparation of compounds of general formula IV or IVa as defined in claim 3 which comprises deprotecting a corresponding compound of formula I as defined in claim 1 by removal of the dienophile residue X and subsequently, optionally after conversion of the group R¹ to another group R¹, isomerising the compound of formula IV thus obtained to a compound of formula IVa.

1130

47283K

0078704

- 68 -


9. A process as claimed in claim 6 or claim 8 wherein a product is obtained in which R^1 represents a hydroxyl group and the said hydroxyl group is converted into a halogen atom or a hydrocarbylsulphonyloxy group.

10. A process as claimed in any one of claims 6, 8 and 9 wherein a product is obtained in which R^1 represents a halogen atom or a hydroxyl or hydrocarbylsulphonyloxy group which product is converted into a product wherein R^1 represents a group of formula $-ZR^3$ as defined in claim 1 other than a hydroxyl group.

4N139-418AC

Claims

1. A process for the preparation of compounds of the general formula



• 1131

- (wherein R represents a hydrogen atom or a hydroxyl protecting group, Y represents a hydrogen atom or an optionally protected hydroxyl group, X represents the residue of a dienophile and either R^1 represents a halogen atom a hydrocarbylsulphonyloxy group or a group of the formula $-ZR^3$ (in which Z represents -O-, -S-, -SO-, -NR⁴- or -CR^{4,5}- and R³, R⁴ and R⁵, which may be the same or different, each represent a hydrogen atom or a straight or branched aliphatic group having 1-12 carbon atoms and which may optionally carry one or more substituents) and R² represents a hydrogen atom or R¹ and R² together represent an oxo group or an optionally substituted alkylidene group, except that R¹ and R² together with the group $-\text{CH}(\text{CH}_3)\text{CH}-$ to which they are attached do not represent a group having the branched 17 β -hydrocarbyl side chain skeleton of vitamin D₂ or vitamin D₃)

47283K

1132

47283K

0078704


- 4 -

Austrian Claims

0078704

- 2 -

which comprises subjecting a compound of formula III,



- (wherein R, Y and X are as defined above) to oxidative cleavage to form an aldehyde of formula I (in which R¹ and R² together represent an oxo group) and subsequently, if desired
- either reacting the said aldehyde of formula I with a Wittig reagent to give a compound of formula I wherein R¹ and R² together represent an optionally substituted alkylidene group, the double bond of which may then, if desired, be reduced.
- or reducing the said aldehyde of formula I to give a compound of formula I wherein R¹ represents a hydroxyl group, the said hydroxyl group being then optionally converted into a halogen atom, a hydrocarbylsulphonyloxy group or a group of formula -ZR³ as defined above other than a hydroxyl group.
2. A process as claimed in claim 1 in which the dienophile is SO₂ or a diacylazo compound.
3. A process for the preparation of compounds


1133

47233K

0078704

- 3 -

of general formula IV or IVa,



- (wherein R, Y, R¹ and R² are as defined in claim 1) which comprises deprotecting a corresponding compound of formula I as defined in claim 1 by removal of the dienophile residue X and subsequently, optionally after conversion of the group R¹ to another group R¹, isomerising the compound of formula IV thus obtained to a compound of formula IVa.
4. A process as claimed in any preceding claim for the preparation of compounds of general formula I, IV or IVa wherein R¹ represents a halogen atom, a hydroxyl or tosyloxy group or a group of formula:
- 15
- (in which Z' represents -O-, -S-, -NH- or -SO- and R⁶ represents a hydrogen atom or a hydroxyl protecting group) and R² represents a hydrogen atom or R¹ and R² together represent an alkylidene group having 1 to 8 carbon atoms optionally substituted by one or more substituents selected from halogen atoms and optionally protected hydroxyl groups.

1134




47233K

0078704

0078704

- 4 -

5. A process as claimed in any preceding claim wherein a product is obtained in which R^1 represents a hydroxyl group and the said hydroxyl group is converted into a halogen atom or a hydrocarbylsulphonyloxy group.
6. A process as claimed in any preceding claim wherein a product is obtained in which R^1 represents a halogen atom or a hydroxyl or hydrocarbylsulphonyloxy group which product is converted into a product wherein R^1 represents a group of formula $-ZR^3$ as defined in claim 1 other than a hydroxyl group.



1136

47283K

1136

47283K